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Marinesco-Sjögren syndrome (MSS) is a rare 
autosomal recessive neurodegenerative 
disorder characterized by cerebellar ataxia 
due to cerebellar cortical atrophy, infantile- or 
childhood-onset bilateral cataracts, 
progressive myopathy, and mild to severe 
mental retardation. Additional features 
include hypergonadotropic hypogonadism, 
various skeletal abnormalities, short stature, 
and strabismus. The neuroradiologic 
hallmarks are hypoplasia of both the vermis 
and cerebellar hemispheres. The 
histopathologic findings include severe 
cerebellar atrophy and loss of Purkinje and 
granule cells. The common pathologic 
findings in muscle biopsy are variation in 
muscle fiber size, atrophic fibers, fatty 
replacement, and rimmed vacuole formation. 
The presence of marked cerebellar atrophy 
with myopathy distinguishes MSS from 
another rare syndrome, the congenital 
cataracts, facial dysmorphism, and 
neuropathy syndrome (CCFDN). 
 
Previously, work by others had resulted in the 
identification of an MSS locus on 
chromosome 5q31. A subtype of MSS with 
myoglobinuria and neuropathy had been 
linked to the CCFDN locus on chromosome 
18qter, at which mutations in the CTDP1 
gene had been identified. We confirmed 
linkage to the previously identified locus on 
chromosome 5q31 in two Finnish families 
with eight affected individuals, reduced the 
critical region by fine-mapping, and identified 
SIL1 as a gene underlying MSS. We found a 
common homozygous founder mutation in all 
Finnish patients. The same mutation was also 
present in patient samples from Norway and 
Sweden. Altogether, we identified eight 
mutations in SIL1, including nonsense, 
frameshift, splice site alterations, and one 
missense mutation. SIL1 encodes a nucleotide 
exchange factor for the endoplasmic 
reticulum (ER) resident heat-shock protein 70 
chaperone GRP78. GRP78 functions in 
protein synthesis and quality control of the 
newly synthesized polypeptides. It senses and 
responds to stressful cellular conditions.  
 
We showed that in mice, SIL1 and GRP78 
show highly similar spatial and temporal 
tissue expression in developing and mature 
brain, eye, and muscle. Studying endogenous 
proteins in mouse primary hippocampal 
neurons, we found that SIL1 and GRP78 
colocalize and that SIL1 localizes to the ER. 
We studied the subcellular localization of two 
mutant proteins, a missense mutant found in 
two patients and an artificial mutant lacking 
the ER retrieval signal, and found that both 
mutant proteins formed aggregates within 
the ER. Well in line with our findings and the 
clinical features of MSS, recent work by Zhao 
et al. showed that a truncation of SIL1 causes 
ataxia and cerebellar Purkinje cell loss in the 
naturally occurring woozy mutant mouse. 
Prior to Purkinje cell degeneration, the 
unfolded protein response is initiated and 
abnormal protein accumulations are present. 
MSS thus joins the group of protein 
misfolding and accumulation diseases. These 
findings highlight the importance of SIL1 and 
the role of the ER in neuronal function and 
survival. 
 
The results presented in this thesis provide 
tools for the molecular genetic diagnostics of 
MSS and give a basis for future studies on the 
molecular pathogenesis of MSS. 
Understanding the mechanisms behind this 
pleiotropic syndrome may provide insights 
into more common forms of ataxia, 







Cells are the building blocks of human life, 
and almost all human cells have a nucleus 
which contains the genetic material. The 46 
human chromosomes and mitochondrial DNA 
comprise the genome, which combines the 
genetic information from previous 
generations and makes up the blueprint for a 
human being. Cells are complex factories of 
life, and all their processes have to meet 
certain criteria for the entity to function 
properly. A cell needs quality control 
mechanisms to identify and prevent mistakes 
during its essential activities: the 
chromosomal DNA, the transcribed mRNA as 
well as the newly synthesized proteins are 
subject to continuous proofreading. 
 
Approximately 6330 Mendelian monogenic 
syndromes have been characterized in man 
(9th January, 2008; www.ncbi.nlm.nih.gov/ 
Omim/mimstats.html). In a little over half of 
them the molecular basis, the defective gene, 
is known. Each syndrome has a unique 
combination of phenotypic features, and each 
syndrome differs from another by only one or 
few of those features. When comparing the 
number of human protein coding genes, 
currently estimated to be 25000, to the 
number of genes implicated in disease, it has 
been argued that the majority of single gene 
defects that give rise to disease have not been 
identified yet. Although in recent years there 
have been many advances in genetics finding 
the right diagnosis for a patient with a rare 
disorder is still demanding, as is finding a 
major genetic risk factor for a common 
disease. 
In 1931 the Romanian neurologist Georges 
Marinesco published with his associates a 
novel syndrome in four individuals from a 
single family (Marinesco et al. 1931). Later, a 
Swedish professor Torsten Sjögren saw four 
similar cases and identified 10 additional 
patients belonging to three families, carried 
out thorough genetic statistical analysis and 
concluded that the disorder is hereditary and 
transmitted in an autosomal recessive manner 
(Sjögren 1950). The syndrome with cerebellar 
ataxia, congenital cataracts, delayed motor 
development and varying degrees of mental 
retardation is thus called Marinesco–Sjögren 
syndrome (MSS), even though it was probably 
first described in 1904 by Ernest Emil 
Moravscik (Alter et al. 1968; Superneau et al. 
1985). Unfortunately, Moravscik chose to 
write to a Hungarian journal, Orvosi Hetilap, 
which may have restricted his audience 
(Brogdon et al. 1996). MSS is a rare disorder: 
although it was characterized over a century 
ago, there are only 200 published cases world 
wide, including the four patients from Finland 
that were published by Riitta Herva and her 
colleagues in 1987. 
 
Marinesco-Sjögren syndrome has been one of 
the syndromes described in Mendelian 
Inheritance in Man since the book’s first 
edition (McKusick 1966). Today, the online 
version of the book, OMIM (Online Mendelian 
Inheritance in Man; www.ncbi.nlm.nih.gov/ 
Omim), also links the syndrome with its 
defective gene SIL1, encoding a nucleotide 
exchange factor. 
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5 REVIEW OF THE LITERATURE 
 
5.1 Autosomal recessive cerebellar 
ataxias 
 
Cerebellar ataxias are a heterogeneous group 
of neurodegenerative disorders. The 
hereditary ataxias are all characterized by 
motor incoordination due to cerebellar 
dysfunction and the group consists of a large 
number of autosomal dominant ataxias and 
ataxias with autosomal recessive, X-linked, or 
mitochondrial inheritance. Different types of 
hereditary ataxia have overlap in their clinical 
presentation and it may be difficult to 
distinguish between them even when the 
family history is known (Opa et al. 2002). The 
dominant forms share certain characteristics: 
the onset is in adulthood, anticipation (i.e. the 
tendency of a disease to become more severe 
or to start at earlier ages in successive 
generations) may be present, which is 
explained by the fact that many forms are 
due to repeat expansion mutations. 
Autosomal recessive ataxias are usually early 
onset presenting before the age of 20 years 
(Harding 1983). A comparison of selected 
autosomal recessive cerebellar ataxia types is 
presented in Table 1. 
 
Friedreich’s ataxia (FRDA, MIM 229300) is 
world wide the most common form of 
autosomal recessive ataxia, but in Finland its 
incidence is much lower (Juvonen et al. 
2002). FRDA is clinically characterized by 
slowly progressive ataxia, dysarthria, absent 
reflexes in lower limbs, sensory loss, and 
pyramidal signs. Skeletal deformities, like 
scoliosis and high arch foot, and 
cardiomyopathy are found in the majority of 
the patients, and they have increased 
frequency of impaired glucose tolerance and 
diabetes. In a typical case, symptoms begin in 
late childhood or adolescence and the death 
typically occurs in the fourth decade. Some 
patients have atypical presentation with onset 
after 25 years, retained tendon reflexes, and 
absence of extensor plantar response (Durr et 
al. 1996). 98% of patient alleles have a GAA 
repeat expansion in the first intron of the 
frataxin (FXN) gene (Campuzano et al. 1996) 
encoding a mitochondrial anti-apoptotic 
protein, which prevents mitochondrial 
damage and reactive oxygen species 
production and is involved in iron 
homeostasis (Condo et al. 2006). Point 
mutations in FXN are rare, and depending on 
the mutation, they can cause 
indistinguishable or atypical phenotypes when 
combined with the repeat expansion 
(Delatycki et al. 2000).  
 
Ataxia-telangiectasia (AT, MIM 208900) is the 
second most frequent autosomal recessive 
ataxia. The hallmark features of AT include 
progressive cerebellar ataxia with onset 
typically before three years of age, 
telangiectases in skin and conjunctiva of the 
eye, immune defects, and predisposition to 
malignancy (Perlman et al. 2003). Oculomotor 
apraxia is frequently present. Magnetic 
resonance imaging (MRI) shows cerebellar 
atrophy and serum α-fetoprotein levels are 
usually elevated. AT results from mutations in 
the ataxia telangiectasia mutated (ATM) gene 
(Savitsky et al. 1995) encoding a 
serine/threonine protein kinase (Canman et 
al. 1998). The large size of ATM with no 
mutation hotspots makes genetic diagnostics 
challenging. 
 
Ataxia with isolated vitamin E deficiency 
(AVED; MIM 183090) is caused by mutations 
in the α-tocopherol transfer protein gene, α-
TTP, leading to impaired incorporation of α-
tocopherol into lipoproteins and inefficient 
recycling of plasma vitamin E (Ouahchi et al. 
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10 years, and in its classical form AVED is very 
similar to FRDA. The absence of 
cardiomyopathy and diabetes in AVED 
distinguishes it from FRDA. Diagnosis is based 
on low levels of vitamin E in serum. The 
condition is treatable with vitamin E 
supplementation (Koenig 2003). 
 
Some autosomal recessive ataxias have 
specific geographical distributions. In Finland, 
the most relevant ones are infantile-onset 
spinocerebellar ataxia (IOSCA, MIM 271245), 
mitochondrial recessive ataxia syndrome 
(MIRAS), and progressive myoclonus epilepsy 
of Unverricht-Lundborg type (EPM1, MIM 
254800). The onset of IOSCA is between 9 
and 18 months of age and the characteristic 
features include atrophy of the cerebellum, 
brain stem and spinal cord, ataxia, athetosis, 
loss of deep tendon reflexes, and sensory 
axonal neuropathy (Koskinen et al. 1994; 
Nikali et al. 2005). Other symptoms include 
ophthalmoplegia, hearing loss, optic atrophy, 
and female primary hypergonadotropic 
hypogonadism. Recessive mutations in the 
C10orf2 gene (chromosome 10 open reading 
frame 2; also called PEO1) encoding a 
mitochondrial helicase Twinkle underlie 
IOSCA, whereas dominant mutations are 
associated with progressive external 
ophthalmoplegia (Spelbrink et al. 2001). 
MIRAS is a recently identified ataxia syndrome 
(Rantamäki et al. 2001) which has been 
associated with mutations in the polymerase γ 
(POLG) gene involved in the replication and 
repair of mitochondrial DNA (Van Goethem et 
al. 2004; Hakonen et al. 2005). MIRAS 
manifests at variable age of onset (5-41 years) 
with heterogenous symptoms: ataxia, 
peripheral neuropathy, dysarthria, mild 
cognitive impairment, involuntary 
movements, psychiatric symptoms, and 
epileptic seizures. In EPM1 ataxia is a cardinal 
feature, but it is usually present at later stages 
of the disease with the main clinical 
presentation of stimulus-sensitive myoclonus 
and generalized tonic-clonic seizures 
(Lehesjoki et al. 2004).  
 
5.2 Marinesco-Sjögren syndrome 
5.2.1 Clinical manifestations 
 
Marinesco-Sjögren syndrome (MSS, MIM 
248800) is an autosomal recessive disorder 
with marked phenotypic variability (Williams 
et al. 1996; Lagier-Tourenne et al. 2003; 
Slavotinek et al. 2005). The syndrome is a 
panethnic disease with 200 published cases 
(Orphanet Reports Series 2007), but exact 
prevalence figures are not available. Clinically, 
the patients described in the literature form a 
heterogeneous entity, and can be divided into 
classical MSS and MSS-like groups. Typically, 
classical MSS is characterized by cerebellar 
atrophy with ataxia, early-onset cataracts, 
mild to severe mental retardation, and 
myopathy. Additional features include 
hypergonadotropic hypogonadism, short 
stature, various skeletal abnormalities, and 
strabismus (Williams et al. 1996; Lagier-
Tourenne et al. 2002; Slavotinek et al. 2005). 
The common clinical features of MSS are 
summarized in Table 2. 
 
The cerebellar signs dominate the central 
nervous system (CNS) symptoms in MSS 
(Williams et al. 1996; Lagier-Tourenne et al. 
2002; Slavotinek et al. 2005). Delayed motor 
milestones are among the first clinical signs. 
Gait or truncal ataxia is one of the most 
frequent symptoms. Dysarthria, nystagmus, 
and intention tremor have been noted in 
many cases. In classical MSS neuroimaging 
studies such as MRI and computed 
tomography (CT) show cerebellar atrophy, 
which is usually more pronounced in the 
vermis than in the hemispheres (Katafuchi et 
al. 1990; McLaughlin et al. 1996; Georgy et 
al. 1998; Harting et al. 2004). The cerebellar 
fissures are widened and the fourth ventricle 
Review of the literature 
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is enlarged (Katafuchi et al. 1990; Harting et 
al. 2004). Atrophy of the cerebral cortex and 
the brainstem have been reported (Bromberg 
et al. 1990; Katafuchi et al. 1990), as well as 
atrophy of the pons and medulla oblongata 
(Sasaki et al. 1996). A T2-hyperintense 
cerebellar cortex has recently been reported 
in three patients with MSS, who also 
presented reduced N-acetylaspartate and 
elevated myo-inositol metabolite ratios in 
proton magnetic spectroscopy of the 
cerebellum (Harting et al. 2004). One patient 
with MSS showed decreased glucose 
metabolic rate in the thalamus with positron 
emission tomography (Bromberg et al. 1990). 
Four patients had experienced epileptic 
seizures (Goto et al. 1990; McLaughlin et al. 
1996). MSS patients have variable degrees of 
developmental delay, and the slow 
progression of neurological deterioration led 
to the search for a metabolic defect 
(McLaughlin et al. 1996). Lysosomal inclusions 
in cultured fibroblasts have been observed in 
one report (Walker et al. 1985), but the 
finding has not been confirmed (Herva et al. 
1987). 
 
The neuromuscular manifestations described 
so far show considerable variation. 
Hypotonia, slowly progressive muscle 
weakness, and atrophy suggesting chronic 
myopathy have been the most frequent 
findings (Andersen 1965; Alter et al. 1968; 
Herva et al. 1987; Superneau et al. 1987). 
Electromyography (EMG) typically shows only 
myopathic features (Chaco 1969; Komiyama 
 
Table 2. Clinical features of MSS. 
   
 (Slavotinek et al. 2005) 
75 cases 
(Williams et al. 1996) 
125 cases 
Cerebellar signs   
   Truncal / limb ataxia 72% >98% cerebellar 
dysfunction 
   Dysarthria 45%  
   Nystagmus 36%  
   Intention tremor 16%  
Ophthalmological features   
   Cataracts 91% 98% 
   Strabismus 44%  
Other neurological signs   
   Truncal / limb hypotonia 53% 89% hypotonia, muscle 
weakness or atrophy 
   Muscle atrophy 51%  
   Muscle weakness 36%  
Ortopedic manifestations   
   Pes planus / planovalgus 28% 46% skeletal anomalies 
   Genu valgum 20%  
   Scoliosis 19%  
   Kyphoscoliosis 16%  
   Joint contractures 17%  
   Pectus deformities 9%  
   
Adapted from a table by Sl avotinek et al (Slavotinek et al. 2005), where following cases were included 
in the review: (Alter et al. 1962; Skre et al. 1977; Hakamada et al. 1981; Alexianu et al. 1983; Walker 
et al. 1985; Herva et al. 1987; Superneau et al. 1987; Sewry et al. 1988; Komiyama et al. 1989; 
Bromberg et al. 1990; Katafuchi et al. 1990; Tachi et al. 1991; Torbergsen et al. 1991a; Kodama et al. 
1992; Zimmer et al. 1992; Ishikawa et al. 1993; Brogdon et al. 1996; McLaughlin et al. 1996; Williams 
et al. 1996; Farah et al. 1997; Muller!Felber et al. 1998; Aguglia et al. 2000; Reinker et al. 2002). 
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et al. 1989; Torbergsen et al. 1991b). 
Demyelinating polyneuropathy (Zimmer et al. 
1992), axonal polyneuropathy (Skre et al. 
1976) or both (Alexianu et al. 1983; Müller-
Felber et al. 1998) have also been described. 
Serum creatine kinase (CK) concentrations are 
normal (Superneau et al. 1987; Torbergsen et 
al. 1991a) or moderately increased, usually 2–
4 fold the upper normal limits.  
 
The bilateral cataracts have been stated as 
congenital, but there are several reports on 
rapid postnatal development of lens opacities 
(Herva et al. 1987; Ishikawa et al. 1993; 
McLaughlin et al. 1996; Farah et al. 1997; 
Slavotinek et al. 2005). In only a few cases 
has the type of cataract been stated. In 
addition to variable single reports, posterior 
capsular opacities have been reported 
(Ishikawa et al. 1993; Farah et al. 1997). The 
eyes are typically operated on in the first 
decade of life. Strabismus is a frequent 
finding and optic atrophy was present in 
three cases (Dotti et al. 1993). 
 
Radiography of the bones may help to 
determine the extent of skeletal involvement. 
In the literature, the most distinguishable 
skeletal features are shortening of 
metacarpals and metatarsals, shortening of 
phalanges, and deformation of the sternum. 
In addition, small posterior cranial fossa, 
scoliosis and kyphoscoliosis, scalloped 
vertebral bodies, gracile bones, pes 
planovalgus, and valgus deformities of elbows 
and hips are present (Brogdon et al. 1996; 
Reinker et al. 2002). 
 
Although atypical findings like optic atrophy, 
seizures, hearing loss, and peripheral 
neuropathy have been reported, it is 
unknown if these are rare manifestations of 
MSS or features of a distinct disorder 
(Williams et al. 1996; Lagier-Tourenne et al. 
2003; Slavotinek et al. 2005). 
 
5.2.2 Natural history 
 
MSS patients are usually born after 
uncomplicated pregnancies. Muscular 
hypotonia is typically noted in early infancy. 
The development of a child sometimes 
deteriorates after febrile illness (Slavotinek et 
al. 2005). Muscular weakness is already 
noticed during the first decade of life in the 
distal muscles of the extremities, and some 
patients are never able to walk without 
assistance (Alter et al. 1968; Herva et al. 
1987; Superneau et al. 1987). Later, patients 
show truncal ataxia, dysdiadochokinesia, and 
dysarthria. The motor functions of the 
patients worsen progressively, followed by 
stabilization of the functional state at varying 
ages and at variable degrees of severity.  
 
Patients show delayed developmental 
milestones and their mental performance 
varies usually from mild to moderate mental 
retardation (Lagier-Tourenne et al. 2003). 
Although many of the patients are severely 
handicapped in their adulthood, the life span 
of patients with MSS is near to normal.  
 
5.2.3 Histopathologic findings 
 
Under light microscopy variation in muscle 
fiber size, atrophic fibers, fat accumulation, 
and rimmed vacuole formation are observed 
(Herva et al. 1987; Sewry et al. 1988; Suzuki 
et al. 1997). Rimmed vacuoles were most 
evident in samples taken at older ages (Herva 
et al. 1987). In electron microscopy, 
autophagic vacuoles with myeloid bodies 
beneath the sarcolemma or near the nucleus, 
and a perinuclear dense double-membrane 
structure suggested to be specific to MSS, are 
seen (Herva et al. 1987; Sewry et al. 1988; 
Sasaki et al. 1996).  
 
Sural nerve biopsy has been performed on 
four MSS patients. The findings have been 
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presence of segmental demyelination 
(Hakamada et al. 1981; Alexianu et al. 1983; 
Farah et al. 1997), and features of chronic 
axonal degeneration (Farah et al. 1997), 
which was proposed to be secondary to the 
segmental demyelination (Alexianu et al. 
1983). One case was reported to have normal 
findings in sural nerve biopsy (Mahloudji et al. 
1972). 
 
Autopsy findings in three patients have 
shown severe cerebellar atrophy with loss of 
Purkinje and granule cells (Todorov 1965; 
Mahloudji et al. 1972; Skre et al. 1977). The 
remaining Purkinje cells were mostly 
vacuolated or binucleated. The brain lesions 
were almost exclusively limited to the 
cerebellum, although in one case cell loss and 
atrophy were present in pons and medulla 
(Mahloudji et al. 1972). The cerebellar 
Purkinje and granule cell loss, however, does 
not extend to the IX and X lobules (nodulus, 
flocculus, and paraflocculus ventralis) 
(Todorov 1965).  
 
There is only one report of histological 
findings in ovary and testis (Bassoe 1956). The 
ovarian tissue showed fibrous changes and 
only a few scarred follicles were observed. 
Examination of the testis showed large 
aggregations of Leydig cells, scanty testicular 
canals with few Sertoli cells, and most of the 
tissue was replaced by a hyaline substance. 
 
5.2.4 Differential diagnosis 
 
Other syndromes presenting with cerebellar 
atrophy and ataxia (see above) should be 
considered as differential diagnoses. This is 
especially true in a case of an affected child 
without family history, when all MSS features, 
e.g. cataract and hypergonadotropic 
hypogonadism, may not be present 
(McLaughlin et al. 1996). In MSS, the degree 
of mental retardation may vary as well as the 
myopathic features.  
 
The congenital cataracts, facial dysmorphism, 
and neuropathy syndrome (CCFDN, MIM 
604168) shares with MSS the key features of 
ataxia, cataracts, psychomotor delay and 
hypogonadism (Tournev et al. 1999). The 
presence of more severe mental retardation, 
marked cerebellar atrophy leading to severe 
ataxia, myopathy with specific features on 
muscle biopsy, and absence of peripheral 
neuropathy and microcornea distinguishes 
MSS from CCFDN (Lagier-Tourenne et al. 
2002).  
 
Some recent reports have described disorders 
clinically similar to, but genetically different 
from, MSS. An X-linked syndrome, cataract, 
ataxia, short stature, and mental retardation 
(CASM, MIM 300619), affects males while 
female carriers present only cataracts (Guo et 
al. 2006). A Marinesco-Sjögren-like syndrome 
was reported in two siblings sharing most of 
the clinical features found in MSS but without 
marked cerebellar atrophy (Schulz et al. 
2007). As additional symptoms the patients 
presented external ophthalmoplegia and 
dysphagia. 
 
There are some other rare, mainly autosomal 
recessive disorders that resemble MSS. The 
clinical entities include the Cataract-ataxia-
deafness-retardation syndrome (MIM 
212710), which differs from MSS by the 
presence of sensorineural hearing loss and 
polyneuropathy (Begeer et al. 1991), and 
familial Danish dementia (FDD, MIM 117300), 
a dominant disorder where cataracts and 
ataxia occur later in life than in MSS, and 
where the patients have dementia or 
psychosis (Vidal et al. 2000). VLDLR-
associated cerebellar hypoplasia 
(Dysequilibrium syndrome; MIM 224050) 
found in Hutterites shares many features with 
MSS including cerebellar atrophy, cataracts, 
psychomotor delay, short stature, strabismus, 
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and hypotonia, but lacks progressive 
myopathy (Boycott et al. 2005). In aniridia, 
cerebellar ataxia, and mental deficiency 
(Gillespie syndrome; MIM 206700) two main 
MSS features, cataracts and myopathy, are 
not present and the patients have aniridia 
(Nelson et al. 1997). Ataxia-microcephaly-
cataract syndrome (MIM 208870) has been 
reported in only one family, in which ataxia-
telangiectasia was also present (Ziv et al. 
1992). In addition, several other syndromes 
share some of the main clinical features with 
MSS, but they are distinguishable due to 
additional features. For example, in 
pseudohypoparathyroidism (PHP, MIM 
103580) mental retardation, cataracts, short 
stature, and short metacarpals are present, 
but the patients have neither ataxia nor 
myopathy (Brogdon et al. 1996). 
 
5.2.5 Molecular genetics 
 
Two loci have been linked to MSS. Lagier-
Tourenne et al. (Lagier-Tourenne et al. 2003) 
used a homozygosity mapping strategy in two 
large consanguineous families of Turkish and 
Norwegian origin with the strict clinical 
features of MSS. They localized the MSS locus 
to a 9.3 cM interval on chromosome 5q31 
between markers D5S1995 and D5S436.  
 
A second locus on chromosome 18qter was 
identified in three Roma families with the 
phenotype of MSS with myoglobinuria and 
demyelinating neuropathy (Merlini et al. 
2002). This locus was first described in 
families with CCFDN syndrome (Angelicheva 
et al. 1999), which is one of the differential 
diagnoses for MSS. When a homozygous 
mutation leading to aberrant splicing of the 
CTDP1 gene was shown to underlie CCFDN, a 
panel of 14 non-Roma patients with MSS was 
screened and no mutations were found 
(Varon et al. 2003). It is not clear whether the 
original reports of a subtype of MSS with 
myoglobinuria and neuropathy (Müller-Felber 
et al. 1998; Merlini et al. 2002) actually 
described patients with CCFDN rather than 
MSS. 
 
5.3 The Human Genome Project  
 
The Human Genome Project (HGP), which 
achieved its main goal of sequencing >98% 
of the gene-containing part of the human 
genome in April 2003, has changed the field 
of genetics completely. This historic project 
started in 1990 as an international effort, 
which aimed at identifying all human genes, 
determining the complete sequence of the 
human genome, and making the data 
accessible for further biological studies. One 
of the first milestones of the HGP was the 
construction of genetic and physical maps 
(Collins et al. 2003). The finished euchromatic 
sequence of the human genome is estimated 
to contain 20000-25000 genes, a surprisingly 
low number (The International Human 
Genome Sequencing Consortium 2004). A 
task still remains in sequencing the 20% of 
the human genome that lies within 
heterochromatin (Stein 2004). 
 
Many have stated that the complete 
sequence of the 3 billion bases in the human 
genome is just the end of the beginning. As 
part of the HGP, parallel studies were carried 
out on selected model organisms, such as 
fruit fly (Drosophila melanogaster) and house 
mouse (Mus musculus), to help to develop 
the technology and interpret human gene 
function. Comparative genomics and defining 
the function of the known genes are major 
challenges in the near future. New large-scale 
projects that have been launched include the 
HapMap project, which has just completed 
the second phase haplotype map cataloguing 
common patterns of human DNA sequence 
variation (The International HapMap 
Consortium 2003; 2005; Frazer et al. 2007), 
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the ENCODE (Encyclopedia of DNA elements) 
project (The ENCODE Consortium 2004; 
Birney et al. 2007; Weinstock 2007), in which 
the goal is to identify the functional elements 
within the genome, and the Knockout Mouse 
Project aiming to generate a public resource 
of mouse embryonic stem cells containing a 
null mutation in every gene in the mouse 
genome (Austin et al. 2004).  
 
5.4 Strategies in identifying human 
disease genes  
 
During the past 25 years, disease gene 
identification has changed enormously with 
the help of new techniques. For each project, 
the “method of choice” is chosen based on 
such factors as the family material available, 
mode of inheritance, and the background 
information on the defective pathway. In the 
early years of disease gene identification, 
functional cloning, which is based on the 
knowledge of the basic biochemical defect in 
a particular disease, and the candidate gene 
approach utilizing partial functional 
information about the disease were the only 
methods available (Collins 1995). Later, pure 
positional cloning, i.e. cloning a gene 
identifying first its chromosomal location 
following the laborious identification of the 
genes in the region, was widely used. 
Currently, disease genes are mainly identified 
using the positional candidate gene approach 
relying on a combination of mapping the 
disease to the right chromosomal region and 
searching interesting candidates within this 
interval. Now that the human sequence is 
available from databases, the major constraint 
is to collect family material suitable for 
Mendelian disease gene identification. 
Identifying susceptibility genes for common 
complex diseases remains, however, much 
more difficult. 
 
5.4.1 Functional cloning and other 
position-independent approaches 
 
Prior to the availability of comprehensive 
genetic maps, disease genes were identified 
through knowledge of the defective protein 
product. This method, referred as functional 
cloning, required information about the basic 
molecular pathogenesis of the disease in the 
absence of information about the 
chromosomal position of the gene involved 
(Collins 1992). After determining the peptide 
sequence of the protein involved, the cDNA 
sequence was translated, oligonucleotide 
probes were synthesized and the 
corresponding gene isolated from a cDNA 
library. Functional cloning was successfully 
used in identifying genes such as the 
coagulation factor VIII (F8) gene in hemophilia 
A and the phenylalanine hydroxylase (PAH) 
gene in phenylketonuria (Gitschier et al. 
1984; Kwok et al. 1985). Nevertheless, the 
method was difficult to extend to majority of 
Mendelian diseases because in most heritable 
traits there is no pre-existing information 
about the disease mechanism (Collins 1992). 
 
Identifying disease genes through knowing 
the protein product is not the only position 
independent approach. Well-characterized 
animal models can be helpful. If a defective 
mouse gene is cloned, the human homolog 
becomes a natural candidate, as shown by 
the example of Waardenburg-Shah syndrome 
with pigmentary abnormalities, sensorineural 
deafness, and Hirschsprung disease. The 
defect in the Sox10 (sex determining region 
Y-box 10) gene was first identified in mice 
with aganglionic megacolon, which is 
reminiscent of Hirschsprung disease (Herbarth 
et al. 1998). Later, human patients with 
Waardenburg-Shah syndrome were shown to 
have mutations in SOX10 (Pingault et al. 
1998). More frequently, the knowledge of a 
mouse mutant is combined with that of its 
human counterpart after mapping the disease 
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locus, which was the case in Waardenburg 
syndrome type I (Tassabehji et al. 1992). The 
human locus on chromosome 2q was 
compared to the corresponding region on 
mouse chromosome 1 and the disease-
causing mutations were identified in the 
paired box 3 (PAX3) gene after showing that 
PAX3 was deleted in mice with a similar 
phenotype. Comparing the mRNA expression 
pattern of patient and control samples in 
array experiments may also lead to disease 
gene identification if the defective gene has 
reduced expression. A recent example is Arts 
syndrome with mental retardation, early-
onset hypotonia, ataxia, delayed motor 
development, hearing impairment, and optic 
atrophy. Arts syndrome is linked to Xq22.1-
q24 and oligonucleotide microarray 
expression profiling revealed reduced 
expression levels of the phosphoribosyl 
pyrophosphate synthetase 1 (PRPS1) gene, in 
which patient mutations were shown (de 
Brouwer et al. 2007). 
 
5.4.2 Position-dependent gene 
identification 
 
Positional cloning, first introduced in 1986 
(Royer-Pokora et al. 1986), allowed the 
isolation of disease genes without direct 
information about the basic functional defect. 
Instead, the identification of a defective gene 
is based on its chromosomal map position. In 
positional cloning the defective gene is first 
assigned to a chromosomal position using 
linkage analysis. The candidate interval is 
narrowed using additional markers and finally 
the disease gene is identified among the 
genes in the region (Collins 1992). Among 
the first examples are the identification of the 
cytochrome b beta subunit (CYBB) gene in 
chronic granulomatous disease (Royer-Pokora 
et al. 1986) and the retinoblastoma 1 (RB1) 
gene (Friend et al. 1986). Pure positional 
cloning is practically not used anymore and 
has been replaced by approaches utilizing in 
silico information (Collins 1995). As the 
human sequence and almost all of the 
transcripts within a region are now available, 
positional candidate gene analysis and 
positional functional candidate gene analysis 
combining the positional cloning, candidate 
gene, and functional candidate gene analysis 
methods are at present the most effective 
approaches (Figure 1).  
 
5.4.3 Linkage analysis – defining the gene 
location 
 
The success of a positional cloning project 
relies greatly on the size of the candidate 
region, which is usually identified with the 
help of linkage analysis. First, families where 
the disease of interest is segregating are 
collected and the phenotype is evaluated 
carefully. Families with two or more patients 
are suitable for linkage analysis, but the size 
of the families and number of families needed 
vary depending on the mode of inheritance 
and analysis method used. The likelihood of 
obtaining positive linkage can be predicted 
utilizing statistical analysis.  
 
If there is no known locus for the disease, the 
affected and healthy family members are 
genotyped with multiple polymorphic markers 
covering the genome evenly. The goal is to 
identify one or more markers that segregate 
together with the disease within each family. 
Traditionally, microsatellite markers, short 
polymorphic tandem DNA repeats, are used 
in genome-wide approaches (Weissenbach et 
al. 1992; Ellegren 2004). If the family material 
is large enough, 350-400 informative 
microsatellites covering the genome evenly 
are enough for detecting linkage. Single 
nucleotide polymorphisms (SNPs) are 
nowadays used for genome-wide scans, too. 
Although individually SNPs are less 
informative than microsatellites, the higher 
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density of SNPs gives finer resolution and 
array-based SNP genotyping techniques are 
more high-throughput than genotyping 
microsatellite markers. A genome-wide scan 
using 6000-500000 SNPs may also require 
less fine-mapping.  
 
Homozygosity mapping is a method utilizing 
a consanguineous family structure to map an 
autosomal recessive disease. The term 
autozygosity denotes homozygosity for 
markers identical by descent, which means 
inherited from a defined common ancestor. 
The application was first introduced by Lander 
and Botstein (Lander et al. 1987), and has 
been used in mapping the genes for diseases 
that are more common in population isolates 
(Peltonen et al. 1999). In Finland, the 
population structure due to national and 
regional isolation has lead to unique 
assortment of hereditary diseases, denoted as 
the Finnish Disease Heritage (FDH) (Norio 
2003a). In the majority of FDH diseases one 
founder mutation accounts for almost all 
disease alleles thus allowing the exploitation 
of homozygosity mapping (Norio 2003b). 
 
Linkage analysis is based on the fact that two 
closely related loci on the same chromosome 
are inherited together more often than would 
be expected by chance. The recombination 
fraction (θ) indicates the probability that a 
recombination, that is a crossing-over event 
during meiosis, is observed between the two 
loci. Two loci are genetically linked when θ is 
less than 0.5 (or 50%). The genetic distance 
between two loci is measured in 
centiMorgans (cM). If two loci are 1 cM apart 
from each other, there is a 1% chance of 
recombination between these loci as the 
chromosome is passed to the next 
generation. In other words, 100 meioses are 
required to observe one recombination. The 
genetic distance is not linear compared to 
physical distance, but in general 1 cM 
corresponds to 1 Mb. The recombination 
fractions differ between females and males, 
and in most mammals female genetic maps 
are longer than those for males (Kong et al. 
2002; Coop et al. 2007). Certain areas in the 
genome are more prone to recombination 
than others and it has been estimated that 
80% of crossing over events take place in 10-
20% of genomic sequence, in so called 
Figure 1. Disease gene identification through positional candidate gene analysis. The first 
step is to assign the disease locus to a chromosomal region using linkage analysis. Next, the 
candidate region is narrowed further by fine-mapping. Positional candidate genes are 
prioritized and evaluated for mutations cosegregating with the disease phenotype. 
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recombination hotspots (Coop et al. 2007). 
Despite the highly identical DNA sequence 
between human and chimpanzee, the 
observed locations of recombination hotspots 
do not overlap between these two species 
suggesting that recombination patterns must 
evolve very rapidly (Winckler et al. 2005).  
 
A statistical method is used to evaluate the 
results obtained in a linkage study. 
Calculation of the lod score (Z; logarithm of 
odds) represents the most efficient statistical 
test for proving that the result is not simply 
due to chance (Morton 1955). The lod score 
gives a logarithm based likelihood ratio of a 
pedigree on two alternative hypotheses: is 
linkage with a recombination fraction of θ 
more likely or is it more likely that the two 
loci are not linked (θ = 0.5) (Terwilliger et al. 
1994)? In a set of families the overall lod 
score is obtained by simply adding up 
individual lod scores for each family. The lod 






n = number of non-recombinant offspring 
r = number of recombinant offspring 
 
For a disease with autosomal inheritance lod 
scores of 3.0 or higher are taken as evidence 
of linkage with a 5% chance of error (p = 
0.05), and linkage can be rejected if lod score 
is < -2.0. Lod scores between -2 and +3 do 
not give conclusive results. In parametric, 
model based linkage analysis requiring 
detailed information on the mode of 
inheritance, gene frequencies, and 
penetrance, computer programs such as 
MLINK (Lathrop et al. 1984) and Genehunter 
(Kruglyak et al. 1996) are widely used. MLINK 
is part of the LINKAGE program package, 
which analyzes limited numbers of marker 
loci and is not suitable for multipoint 
analyses. Genehunter allows more effective 
multipoint analyses, but pedigrees need to be 
of moderate size (Nyholt 2002). However, 
model based analysis is usually not optimal 
for complex, nonmendelian diseases, in which 
nonparametric linkage analysis may be the 
method of choice. 
 
Although straightforward, a positional 
cloning project may also have some pitfalls. It 
requires suitable family material, and is 
sensitive to misdiagnosis. Locus heterogeneity 
within individual families can be avoided 
using large families in autosomal dominant 
disorders and homozygosity mapping in 
autosomal recessive diseases, if possible. 
Microsatellite markers distributed across the 
genome at intervals of 10 cM may fail to 
identify a disease locus, but this problem 
could be overcome by using a denser set of 
SNP markers (Chiang et al. 2006). 
 
5.4.4 Chromosomal abnormalities 
 
In some cases it is possible to localize the 
disease gene with the help of associated 
cytogenetic abnormalities. For severe 
dominant diseases, in which the genetic 
cause is de novo, chromosome aberrations 
are especially helpful while linkage analysis is 
not applicable (Breuning et al. 1993). In 
balanced translocations or inversions, the 
breakpoints may directly pinpoint the 
defective gene. For larger, cytogenetically 
visible deletions and microdeletions detected 
with high-resolution comparative genomic 
hybridization analysis, the whole deleted area 
rather than a specific breakpoint becomes the 
candidate region and focus of the search. 
Both balanced translocations and visible 
deletions were utilized in identifying the DMD 
gene underlying Duchenne and Becker 
muscular dystrophies (Monaco et al. 1986; 
Bodrug et al. 1987). A more recent example is 
identification of the DYX1C1 gene underlying 
(1 – θ)n θr 
Z =   log10 
0.5n+r 
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susceptibility to dyslexia (Taipale et al. 2003). 
 
5.4.5 Ancestral haplotypes and linkage 
disequilibrium 
 
After the initial assignment using a genome 
wide scan, the candidate locus is fine-mapped 
with as many informative polymorphic 
markers as possible. Microsatellite markers or 
SNPs that cover the region at high density are 
selected from the databases. The aim of this 
analysis is to identify the key recombinations 
and reduce the size of the candidate region.  
 
After exploiting all recombinants, the 
candidate region may still be large. If a 
founder mutation is probable due to 
population history, the search for a shared 
ancestral haplotype in the families with no 
known relationship may be a reasonable 
approach. Linkage disequilibrium (LD) refers 
to co-occurrence of certain alleles, at loci that 
are close to each other, more often than it 
would be expected by chance. The use of is 
based on the hypothesis that the patients 
have inherited the mutation or susceptibility 
allele from a common ancestor. As a result, 
the alleles of the neighboring loci on the 
same chromosome are also identical and form 
a specific ancestral haplotype. LD mapping 
has been successfully used in Finland 
(Hästbacka et al. 1992; Lehesjoki et al. 1993) 
and is a valuable tool for fine-mapping (de la 
Chapelle et al. 1998).  
 
5.4.6 Gene identification 
 
Before the complete human genome 
sequence became available, the isolation and 
examination of all the genes contained in the 
candidate locus was a major effort. Now, the 
entire human sequence is available in 
electronic format except for some gaps in 
difficult areas (The International Human 
Genome Sequencing Consortium 2004) and 
the identification of genes in the region of 
interest is much easier. There are three widely 
used genome browsers available on-line: the 
University of California, Santa Cruz (UCSC) 
Human Genome Browser Gateway 
(genome.ucsc.edu/cgi-bin/hgGateway), the 
European Bioinformatics Institute's Ensembl 
(www.ensembl.org), and the National Center 
for Biotechnology Information (NCBI) 
MapViewer (www.ncbi.nlm.nih.gov/map 
view). Genome browsers make the sequence 
data easy to access and for example a list of 
annotated genes in a given region can be 
obtained within seconds (Wolfsberg et al. 
2002). 
 
The genes in the candidate region are 
evaluated and prioritized with respect to their 
known or predicted function and tissue 
expression profiles before picking candidate 
genes for sequencing. Appropriate expression 
patterns include the tissues that are affected, 
but need not be restricted to those tissues. 
Databases contain several different types of 
information about gene expression including 
microarray expression data and in situ 
hybridization data for the mouse brain (Allen 
Brain Atlas; www.brain-map.org). The 
function of a gene may be uncovered by 
comparing Gene Ontology terms (GO; 
www.geneontology.org) such as biological 
process, molecular function and cellular 
component, as well as the transmembrane 
domains, and predicted functional 
relationships.  
 
5.4.7 Mutation screening 
 
The final step in identifying a disease gene is 
to detect disease-associated mutations in 
patient samples. There are several mutation 
detection methods with varying sensitivities 
and costs including direct sequencing, 
Southern blotting, as well as PCR-based 
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mutation scanning methods such as single-
strand conformational polymorphism analysis. 
Sequencing is nowadays used as a primary 
method because of its decreased costs. 
However, sequencing of only the coding 
regions of a gene is not an optimal method if 
the mutation lies in an intronic region. 
Alternative methods, such as MLPA (multiplex 
ligation-dependent probe amplification), 
quantitative PCR, or Southern blotting, are 
also required to detect larger chromosomal 
aberration e.g. deletions, insertions or 
duplications.  
 
Distinguishing between a mutation that 
changes the phenotype and a harmless 
polymorphism can be a difficult task. After 
detecting a genomic variant in a patient, the 
segregation of the change is studied. If the 
change is a mutation, it should co-segregate 
with the disease in the family. Mutations 
causing premature termination codons (PTC; 
e.g. nonsense mutations) (Maquat 2004), 
frameshift, or deletion of the whole gene 
almost certainly impact gene function. If a 
missense variation changes a conserved or 
functionally important amino acid, and the 
amino acid change is nonconservative, i.e. 
replacing a polar with a nonpolar amino acid 
(Grantham 1974), the variant is more likely to 
be pathogenic. Substitutions changing 
conserved splice site sequences lead to exon-
skipping and altered splicing, which can have 
an impact on the expression or function of 
the gene. Silent variants affecting the splicing 
regulatory elements are more difficult to 
recognize, but may have deleterious effects 
(Cartegni et al. 2002; Pagani et al. 2004; 
Wang et al. 2007). In addition, a mutation 
should not be detected in a panel of healthy 
control individuals or if detected, it should not 
exceed the estimated carrier frequency in the 
population. In recessive diseases the variant 
should not be detected in homozygous form 
in control samples.  
 
5.4.8 Functional studies 
 
The ultimate proof showing that the detected 
variant is a pathogenic mutation comes from 
functional studies. The type of studies 
applicable is dependent on the known or 
predicted function of the gene. Sequence 
analysis of cDNA can be utilized to detect 
changes that have an impact on the splicing 
of the transcript (Varon et al. 2003). The 
mutation may alter the subcellular localization 
of the protein product or lead to aggregate 
formation (Huynh et al. 2003). If the mutated 
gene encodes for example an ion channel 
protein the effect of the variation may be 
evaluated by expressing the mutated protein 
in a cellular model and determining the 
channel properties, as has been performed 
for mutations in the voltage-gated sodium 
channel SCN1A (Spampanato et al. 2001). 
The defective gene may encode an enzyme 
whose activity can be measured in patient 
cells (Manya et al. 2007). If the mutation 
disrupts known or predicted functional 
domains it is more likely to be pathogenic 
(Escayg et al. 2000), and the mutation may 
impair protein’s interactions with other 
proteins (Laezza et al. 2007). Lastly, the 
variant may be introduced into an animal 
model whose altered phenotype would be 
proof of pathogenicity (Davis et al. 2007). 
 
5.5 Molecular chaperones  
 
Molecular chaperones have an important task 
in assisting the proper folding and assembly 
of other proteins hence preventing 
inappropriate interactions between 
polypeptides and the accumulation of 
misfolded proteins. Chaperones also regulate 
several other cellular processes, including 
protein targeting, transport, recognition of 
misfolded proteins and targeting to 
degradation, and signal transduction (Ellgaard 
et al. 2003; Muchowski et al. 2005). 
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Conditions of cellular stress increase the 
synthesis of certain molecular chaperones, the 
heat shock proteins (HSPs), as a response to 
increases in the amount of misfolded 
proteins. HSPs are classified into six main 
families on the basis of their molecular mass: 
HSP100, HSP90, HSP70, HSP60, HSP40, and 
small heat-shock proteins (sHSPs) (Muchowski 
et al. 2005). Different family members 
function in different subcellular 
compartments, for example stress-70 protein 
(GRP75) in mitochondria, heat shock cognate 
71 kDa protein (HSP7C) in cytosol, and 78 
kDa glucose-regulated protein (GRP78) in the 
ER. 
 
5.5.1 Diseases associated with defective 
chaperones 
 
Some inherited diseases, many of which are 
described in more detail below, are caused by 
mutations in general chaperone proteins. In 
addition, mutations in a few substrate-specific 
chaperones have been identified (Barral et al. 
2004; Muchowski et al. 2005). 
 
Mutations in genes encoding sHSPs cause 
several diseases, some of which have clinical 
overlap with MSS. α-crystallin is composed of 
two subunits, αA-crystallin and αB-crystallin, 
and mutations in these two cause either 
dominantly or recessively inherited congenital 
cataracts (Litt et al. 1998; Pras et al. 2000; 
Berry et al. 2001; Mackay et al. 2003). In 
addition to lens, αB-crystallin is also expressed 
in muscle and other tissues, and mutations in 
this subunit cause myofibrillar myopathies as 
well (Vicart et al. 1998; Selcen et al. 2003). 
Mutations in two other sHSPs, HSP22 and 
HSP27, are associated with axonal Charcot-
Marie-Tooth disease and distal hereditary 
motor neuropathy (Evgrafov et al. 2004; Irobi 
et al. 2004). 
 
Two mitochondrial chaperones have been 
associated with human disease. Mutations in 
heat shock 60kDa protein 1 (HSPD1), 
encoding mitochondrial chaperonin, cause a 
rare form of autosomal dominant pure 
hereditary spastic paraplegia, SPG13 (Hansen 
et al. 2002). An autosomal resessive 
syndrome, dilated cardiomyopathy with ataxia 
(DCMA), characterized by early onset dilated 
cardiomyopathy with conduction defects, 
non-progressive cerebellar ataxia, testicular 
dysgenesis, growth failure, and increase in 
urine organic acids is associated with 
mutation of DNAJC19 gene encoding 
mitochondrial import inner membrane 
translocase subunit TIM14 (Davey et al. 
2006). 
 
One rare form of cerebellar ataxia with 
restricted geographic distribution, autosomal 
recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS), is also most likely a 
chaperone-associated disease. The defective 
gene, the intronless 13-kb SACS gene on 
chromosome 13q11, encodes a novel protein, 
sacsin, with repeated heat-shock domains 
suggesting a chaperone function (Engert et 
al. 2000). The main clinical findings include 
slowly progressive ataxia first noted at gait 
initiation, spasticity of the limbs, slurred 
speech, and nystagmus (Bouchard et al. 
1998). Interestingly, patients with ARSACS 
present atrophy of the superior cerebellar 
vermis and absence of Purkinje cells, features 
that resemble the cerebellar findings of MSS. 
 
5.5.2 Chaperones in neurodegenerative 
diseases 
 
Pathogenesis of many neurodegenerative 
disorders, like Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, 
and spinocerebellar ataxias, is characterized 
by the accumulation of intra- or extracellular 
protein aggregates leading to 
neurodegeneration (Muchowski 2002). 
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Molecular chaperones are often associated 
with the aggregates as they try to overcome 
the toxic effects of aberrantly folded proteins 
until the capacity of the chaperone machinery 
is overloaded (Barral et al. 2004). Thus, 
chaperones provide the first line of defense 
against misfolded aggregation-prone proteins 
and cellular dysfunction. Recent studies in 
animal models of human diseases have 
indicated that chaperones are among the 
most potent suppressors of 
neurodegeneration (Selkoe 2003; Muchowski 
et al. 2005). Molecular chaperones are 
therefore regarded as promising therapeutic 
targets for protein conformational disorders. 
 
5.6 Molecular chaperones of the ER 
 
5.6.1 ER function 
 
The ER is a specialized subcellular 
compartment providing a major protein 
folding and maturation site for secreted, 
plasma membrane and secretory pathway 
organelle (ER, Golgi, lysosomes, and secretory 
vesicles) proteins (Ma et al. 2004; Ni et al. 
2007). The ER differs from other folding 
compartments, e.g. the cytosol and 
mitochondria, by nature of the proteins that 
fold in the ER, by translocation machinery 
that segregates proteins across the 
membrane, by physiological conditions such 
as high oxidizing potential, occasionally high 
Ca2+ concentration, and/or by the presence 
of carbohydrates and glycosylation machinery 
(Brooks 1999; Stevens et al. 1999; 
Hendershot 2004). The ER possesses two 
major chaperone systems: the 
calnexin/calreticulin chaperone system 
assisting the folding of glycoproteins (Ellgaard 
et al. 2003) and the GRP78 chaperone system 
recognizing and binding to proteins 
containing hydrophobic residues (Ma et al. 
2004; Ni et al. 2007). The ER contains at least 
10 general chaperones (Table 3) and some 
protein-specific chaperones whose expression 
is tissue-specific (Stevens et al. 1999).  
 
5.6.2 The GRP78 chaperone system 
 
GRP78 (also called BiP for binding protein, 
HSPA5 for heat shock 70 kDa protein 5, and 
Kar2p in budding yeast) is the primary 
peptide-binding chaperone, which has many 
substrates and recognizes unfolded regions 
on proteins containing hydrophobic residues 
(Hendershot 2004). GRP78, which is encoded 
by the HSPA5 gene, generally localizes to the 
ER but may have a different subcellular 
localization under stressful conditions (Sun et 
al. 2006). Its expression levels are tightly 
controlled and elevated in response to 
physiological or pathological stress, e.g. cell 
differentiation and accumulation of misfolded 
proteins (Hebert et al. 2007).  
 
GRP78 has numerous functions in the ER 
(Figure 2). The first step in the biosynthesis of 
secretory pathway protein involves targeting 
it to the ER. The N-terminal ER-targeting 
sequence enters the ER lumen through a 
translocon co-translationally. GRP78 
maintains the permeability barrier between 
cytosol and the ER by sealing the inactive 
translocon from the luminal side (Figure 2a). 
Once inside the ER the protein associates with 
GRP78 and starts folding (Figure 2b). 
Glycoproteins displaying N-linked glycans in 
their very N-terminal parts are, however, not 
targeted to GRP78 as they fold with the 
assistance of calnexin/calreticulin chaperone 
system. One of the major functions of GRP78 
involves participating in identifying and 
degrading proteins that fail to mature 
properly (Figure 2c). This protein quality 
control system is called ER-associated 
degradation (ERAD). GRP78 binds calcium 
and contributes to calcium homeostasis in the 
ER (Figure 2d). Moreover, GRP78 is involved 
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in the regulation of signal transduction 
pathway called the unfolded protein response 
(UPR). In physiological conditions GRP78 
binds to stress-sensing proteins located in the 
ER membrane and keeps them in an inactive 
state. If unfolded proteins accumulate in the 
ER, GRP78 is released from the stress-sensing 
proteins to interact with unfolded proteins 
(Figure 2e). Like all HSP70 family members, 
GRP78 binds both adenosine triphosphate 
(ATP) and adenosine diphosphate (ADP), 
which regulate its chaperoning functions with 
the exception of calcium storage (shown in 
more detail in Figure 2b). The GRP78 ATPase 
cycle is controlled by two other chaperone 
groups: HSP40 chaperones catalyze the 
Figure 2. Functions of the ER localized chaperone GRP78. A) Nascent proteins are co-translationally 
translocated across the ER-membrane, where GRP78 has been shown to participate in sealing the 
translocon to maintain the permeability barrier between the ER and cytosol. GRP78 may require its 
ATPase activity during protein translocation (Zimmermann et al. 2006). B) The ATPase cycle of GRP78 
regulates its binding and release from nascent protein chains: 1) Chaperone DJB11 binds to the 
unfolded region of a nascent protein and recruits ATP-bound GRP78 to the substrate. 2) DJB11 
stimulates the ATPase activity of GRP78: ATP is hydrolyzed to ADP locking the ADP-bound GRP78 onto 
the unfolded substrate. 3) Nucleotide exchange factor, such as SIL1, catalyzes the release of ADP 
allowing the rebinding of ATP to GRP78. 4) The ATP-bound GRP78 is released from the substrate, 
which is ready for another round of assembly until the folding process is completed. C) GRP78 
recognizes proteins that fail to fold properly and targets them to ER-associated degradation (ERAD). D) 
GRP78 has a role in maintaining ER calcium stores. E) GRP78 also participates in ER stress signaling, as 
in normal physiological conditions GRP78 is bound to ER transmembrane proteins IRE1, PERK, and ATF6 
keeping them inactive. Modified from (Hendershot 2004). 
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hydrolysis of ATP to ADP, which locks GRP78 
to unfolded protein, and nucleotide exchange 
factors SIL1 and HYOU1 induce ADP release 
so that ATP can be substituted back (Tyson et 
al. 2000; Chung et al. 2002). 
 
5.6.3 Cochaperone SIL1 
 
Human SIL1 (also known as BAP for BiP-
associated protein) is a ~54 kDa N-
glycosylated protein with N-terminal ER 
targeting and C-terminal ER retrieval 
sequences (Chung et al. 2002). It acts as an 
adenine nucleotide exchange factor for 
GRP78 and promotes the exchange of bound 
nucleotides by stimulating the dissociation of 
ADP and the subsequent uptake of ATP. SIL1 
was originally characterized in yeast (Boisrame 
et al. 1998; Tyson et al. 2000), and its 
nucleotide exchange factor activity can be 
replaced by another ER resident protein, 
HYOU1 (Steel et al. 2004; Weitzmann et al. 
2006). SIL1 is evolutionarily conserved, with 
85%, 50%, and 23% identical orthologs in 
mouse, zebrafish, and fruit fly, respectively 
(Figure 3). Interestingly, in SIL1 protein the ER 
retrieval motif has undergone several changes 
during evolution and the motif is not as 
highly conserved as it is in e.g. GRP78 or 
other ER resident chaperones (Study III Figure 
2). Recently, a truncation of Sil1 was shown 
to underlie the ataxia in woozy (wz) mutant 
mice (Zhao et al. 2005). Prior to cerebellar 
Purkinje cell degeneration, the wz mice 
develop ubiquitinated protein accumulations 
 
Table 3. The main chaperones in the ER. Modified from (Stevens et al. 1999; Ellgaard et al. 2003; 
Hebert et al. 2007). 
  
Chaperone family / Protein Function 
HSP70  
    GRP78 Protein folding, ERAD, UPR 
  
GrpE!like  
    SIL1 Nucleotide exchange factor for GRP78 
    HYOU1 Possibly protein folding, nucleotide exchange factor for GRP78 
  
HSP40  
    DNJC1 (ERdj1) Cofactor for GRP78 
    SEC63 (ERdj2) Protein translocation across the ER membrane 
    DJB11 (ERdj3) Cofactor for GRP78 
    DNJB9 (ERdj4) Cofactor for GRP78 
    DJC10 (ERdj5) Cofactor for GRP78 
  
Hsp90  
    GRP94 Folding ! limited substrates 
  
Lectins Folding of N!linked monoglycosylated proteins 
    Calnexin  
    Calreticulin  
    EDEM1, EDEM2, EDEM3  
  
Peptidyl!prolyl isomerases Possibly peptidyl!prolyl bond formation 
  
Thiol!disulphide oxidoreductases Oxidation, isomerization and reduction of disulphide bonds 
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in the ER and nucleus of these neurons. In 
order to restore ER homeostasis and 
degradation of the accumulations, unfolded 
protein response is induced in Purkinje cells, 
but the dysfunction of Sil1 leads to specific 
cell death with the exception of cells in 






Figure 3. Conservation of SIL1 amino acid sequence in human (Hs) and mouse (Mm). 
Human SIL1 and the mouse ortholog show 85% identical amino acid sequence. The 
putative ER retention tetrapeptide in the C-terminus is highlighted in gray. 
Hs  MAPQSLPSSRMAPLGMLLGLLMAACFTFCLSHQNLKEFALTNPEKSSTKETERKETKAEE 
Mm  MAPQHLPSTRMASPGMLLGLLLTSCLTLCLSCQNSNNFALTNPEKSIHQESDTKETREEE 
    **** ***:***. *******:::*:*:*** ** ::*********  :*:: ***: ** 
 
Hs  ELDAEVLEVFHPTHEWQALQPGQAVPAGSHVRLNLQTGEREAKLQYEDKFRNNLK----G 
Mm  ELDTEILEVFHPTQEWQTLQPGQAVPAGSHVRMNLQTGVNEVKLQQEDKFQNNLKGFKRG 
    ***:*:*******:***:**************:***** .*.*** ****:****    * 
 
Hs  KRLDINTNTYTSQDLKSALAKFKEGAEMESSKEDKARQAEVKRLFRPIEELKKDFDELNV 
Mm  RRLDINANTYTSQDLKSALAKFKEGTEMENSKDELARQATVKQLFRPIEELKKEFDELNV 
    :*****:******************:***.**:: **** **:**********:****** 
 
Hs  VIETDMQIMVRLINKFNSSSSSLEEKIAALFDLEYYVHQMDNAQDLLSFGGLQVVINGLN 
Mm  VLETDMQIMVRLINKFNSSSSSLEEKVAALFDLEYYVHQMDNAQDLLSFGGLQVVINGLN 
    *:************************:********************************* 
 
Hs  STEPLVKEYAAFVLGAAFSSNPKVQVEAIEGGALQKLLVILATEQPLTAKKKVLFALCSL 
Mm  STEPLVKEYAAFVLGAAFSSNPKVQVEAIEGGALQKLLVILATNQPLPAKKKVLFALCSL 
    *******************************************:***.************ 
 
Hs  LRHFPYAQRQFLKLGGLQVLRTLVQEKGTEVLAVRVVTLLYDLVTEKMFAEEEAELTQEM 
Mm  LRHFPYAQQQFLKLGGLQVLRSLVQEKSAKVLAVRVVTLLYDLVTEKMFAEEEAELTQDS 
    ********:************:*****.::****************************:  
 
Hs  SPEKLQQYRQVHLLPGLWEQGWCEITAHLLALPEHDAREKVLQTLGVLLTTCRDRYRQDP 
Mm  SPEKLQQYRQVQLLPGLQEQGWCEITAQLLALPEHDAREKVLQTLGALLTTCRDRYRQDL 
    ***********:***** *********:******************.************  
 
Hs  QLGRTLASLQAEYQVLASLELQDGEDEGYFQELLGSVNSLLKELR 
Mm  QLSRTLGRLQAEYQALASLELQEGEDDGYFRELLASINSLMKELR 
    **.***. ******.*******:***:***:***.*:***:**** 
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6 AIMS OF THE STUDY 
 
The aim of this study was to gain understanding into the molecular basis of Marinesco-Sjögren 
syndrome. The ultimate aim of the research is to understand the pathogenesis of Marinesco-
Sjögren syndrome, which will be the basis for improved therapies.  
 
The specific aims of this study were to: 
 
1. Localize and refine the MSS locus in Finnish patients with MSS. 
 
2. Identify and initially characterize the gene(s) and gene product(s) underlying MSS in Finnish 
as well as foreign patients. 
 
3. Further describe the clinical features of the MSS patients to gain better understanding of the 
variable clinical characteristics of MSS. 
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7 MATERIALS AND METHODS 
 
7.1 Ethical considerations  
 
The initial research plan was approved by the 
Institutional Review Board of the Kainuu 
Central Hospital (Dnro 22/77/14.5.2003). The 
HUS Ethics Committee for Gynecology and 
Obstetrics, Otology, Ophthalmology, 
Neurology, and Neurosurgery approved an 
extension to the research plan (Dnro 
350/E9/06). 
 
7.2 MSS families and control 
individuals 
 
In total, eight Finnish families participated in 
this study. DNA samples were available from 
14 patients with MSS and 15 family 
members. Two of the families, M1 and M5, 
had been earlier described (Herva et al. 1987). 
Through collaboration we collected 23 
families from different European countries, 
the USA, Australia, and Japan. For the foreign 
families DNA samples were available from 34 
patients with MSS and 42 family members. 
RNA samples were obtained from six patients 
and four parents. The pedigrees of the MSS 
families with SIL1 mutations are shown in 
Figure 4. 
 
Fibroblast cell cultures were available from 
two Finnish and three Swedish and 
Norwegian patients and diagnostic muscle 
specimens from one Swedish and two Finnish 
patients. 
 
The consecutive patient numbering used in 
study I corresponds to patient codes used in 
study II and this thesis as follows: 1: M603, 2: 
M116, 3: M115, 4: M110, 5: M503, 6: 
M113, 7: M114, 8: M403, and 9: M404. 
 
The control samples used in this study were 
from the Centre d’Etude du Polymorphisme 
Humain (CEPH), unrelated Finnish blood 
donors, and unrelated healthy control 
subjects of Turkish and Japanese origin. 
 
7.3 Methods  
 
The methods used in this thesis are 
summarized in Table 4. Each method is 





Table 4. Methods used in this study. 
 
Method Study 
DNA extraction I, II, III 
Polymerase chain reaction (PCR) I, II, III 
Microsatellite marker analysis I, II 
Linkage analysis I, II 
Haplotype analysis I, II 
Direct sequencing  II, III 
Mutation analysis II, III 
In silico sequence analysis (BLAST, 
RepeatMasker, Primer 3, ClustalW, 
AceView) 
II, III 
RNA isolation II, III 
RT!PCR II, III 
Semiquantitative RT!PCR II 
Northern blot analysis II 
Western blot analysis II 
Immunohistochemical stainings II 
Immunofluorescence stainings III 
Fluorescence and bright field 
microscopy 
II, III 
Recombinant DNA techniques 
(cloning) 
II, III 
Site!directed mutagenesis III 
Transient DNA transfections III 




Figure 4. The MSS families with SIL1 mutations. The affected individuals are indicated with filled 
symbols. For simplicity the individuals in the older generations in families M1, M2, M11, and M12 are 
not marked as deceased. Families M1, M4, M5, and M6 are from Finland. Family M2 lives in Sweden, 
but the paternal grandmother was born in Finland. The three Norwegian families are M7, M12, and 
M13. M11 and M20 are of Turkish origin. Family M16 is French and families M21 and M23 are 
Japanese. The DNA samples and patient records (affected persons only) were available from numbered 
individuals. Patient records were available for one additional patient shown in parenthesis. 
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7.3.1 Genotyping and linkage analysis (I, II, 
unpublished) 
 
Genomic DNA was isolated using standard 
methods. The segregation of the MSS 
phenotype with alleles of fluorescently 
labeled microsatellite markers was evaluated 
for two chromosomal loci. Six polymorphic 
markers covering the chromosome 18qter 
locus and ten markers covering the locus on 
5q31 were studied. The marker order, 
intermarker distances, and primer sequences 
were obtained from the Marshfield genetic 
map (Broman et al. 1998), the deCODE 
genetic map (Kong et al. 2002), and NCBI 
sequence based STS map (NCBI Build 35.1). 
The PCR-amplified products were separated 
with an ABI 3730 DNA Analyzer (Applied 
Biosystems) and determined allele sizes were 
determined using the GeneMapper v5.0 
program (Applied Biosystems). The haplotypes 
were constructed manually. The pair-wise lod 
scores were calculated with the help of 
MLINK program from the LINKAGE package 
(Lathrop et al. 1984) assuming autosomal 
recessive inheritance, complete penetrance 
and a disease allele frequency of 0.001. For 
the 5q31 locus, the marker allele frequencies 
were determined from 42 Finnish control 
chromosomes and for the 18qter locus equal 
allele frequencies were assumed.  
 
7.3.2 Mutation analysis (II, III) 
 
The gene content of the interval spanning 
D5S479 and D5S2116 was examined with the 
NCBI Map Viewer, the Ensembl Human 
Genome Browser, and the UCSC Human 
Genome Browser. The exons and exon-intron 
boundaries of SIL1, the ten positional 
candidate genes on chromosome 5q31 
(CTNNA1, EGR1, GFRA3, HBEGF, HSPA9B, 
KLHL3, MYOT, NRG2, SPOCK1, and WNT8A), 
and the three functional candidate genes 
(AARS, HSPA5, and HYOU1) were amplified 
from genomic DNA with intronic primers 
designed with Primer3 (Rozen et al. 2000) or 
ExonPrimer programs. The amplified products 
were purified using the PCR Product Pre-
Sequencing Kit (USB Corporation) and both 
strands were sequenced using the BigDye 
Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems) and an ABI 3730 DNA 
Analyzer. Sequences were analyzed using the 
Sequencher program (version 4.2 to 4.7; 
Gene Codes Corporation). Unrelated control 
individuals were screened for the identified 
mutations by sequencing. 
 
The mutations implied to affect the splicing of 
SIL1 were analyzed from cDNA. Patient and 
control RNA was extracted from freshly 
obtained peripheral blood using the PAXgene 
Blood RNA System (PreAnalytiX) or from 
fibroblast cultures with the RNeasy mini kit 
(Qiagen, Hilden, Germany). The reverse 
transcriptase (RT) PCR reaction was 
performed with the High-Capacity cDNA 
Archive Kit (Applied Biosystems). The cDNA 
was amplified with exonic primers and the 
products were sequenced either directly (see 
above), after purification from a gel (QIAquick 
Gel Extraction Kit; QIAGEN) or after TA-
cloning into the pCRII vector using the TA 
Cloning Kit (Invitrogen).  
 
7.3.3 Gene expression studies (II) 
 
Commercial multiple tissue Northern blots 
(Human Fetal II, Human Brain II, and Human 
Brain V; BD Biosciences Clontech) were 
hybridized with a 1519 bp PCR-generated 
SIL1 cDNA probe covering the whole coding 
region as well as with GAPDH (BD Biosciences 
Clontech). The probes were labeled with 32P-
dCTP using RediPrimeII kit (Amersham 
Pharmacia) and blocked with human placental 
(0.5 mg/ml) and salmon sperm (0.25 mg/ml) 
DNA before hybridization. Hybridizations 
were carried out for 2 h at 65°C in 
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ExpressHyb solution (BD Biosciences 
Clontech), and filters were washed at 60°C 
according to the manufacturer's instructions. 
Semiquantitative RT-PCR was performed from 
BD MTC Multiple Tissue cDNA Panels 
(Human I, Human II, and Human Fetal; BD 
Biosciences Clontech) according to the 
manufacturer’s instructions. A 930 bp SIL1 
fragment (c.584_*+127) was PCR amplified 
and separated by gel electrophoresis. 
 
7.3.4 Immunohistochemistry (II) 
 
Frozen sections from muscle biopsies taken 
for diagnostic examinations from patients and 
controls were stained with a polyclonal goat 
anti-human SIL1 antibody (Abcam Ltd) 
detecting a C-terminal epitope. Sections were 
briefly fixed in –20°C acetone after which the 
protocol described below was followed with 
the exception that no antigen retrieval was 
used. Goat anti-human SIL1 antibody (Abcam 
Ltd) was used at a 1:200 dilution (stock 0.50 
mg/ml). 
 
Paraffin-embedded sections of C57BL mouse 
tissues of embryonic day 12.5, 15.5, and 
18.5, and of postnatal day 5, 14, 60, and 180 
were deparaffinized, hydrated, and treated 
with 10 mmol/l citric acid in microwave oven 
for 5 min for endogenous antigen retrieval. 
Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide for 5 min, and 
nonspecific binding was blocked with 1.5% 
normal serum in 0.1% Tween-phosphate-
buffered saline (PBS) for 30–60 min. The 
primary antibodies were incubated overnight 
at 4°C in 0.1% Tween-PBS. Goat anti-human 
SIL1 antibody (Abcam Ltd) was used at a 
1:400 dilution (stock 0.50 mg/ml) and rabbit 
anti-human HSPA5 antibody (Sigma) at a 
1:1500 dilution (stock 10.3 mg/ml). Western 
blot analyses were performed to verify specific 
cross-reactivity of both antibodies with mouse 
tissue (data not shown). An avidin-biotin 
immunoperoxidase system (Vectastain Elite 
ABC Kit, Vector Laboratories) was utilized to 
visualize the bound antibody with 
diaminobenzidine (Sigma) as chromogen. The 
sections were counterstained with 
hematoxylin. Non-immune serum or PBS was 
used instead of the primary antibody for 
negative controls.  
 
7.3.5 The expression plasmid and site-
directed mutagenesis (III) 
 
The ORF of the human SIL1 cDNA was cloned 
in frame into the aminoterminal 
hemagglutinin (HA) tag containing pAHC 
expression vector (kindly provided by T. 
Mäkelä, University of Helsinki, Finland). Two 
nucleotide changes, c.1370T>C (p.Leu457Pro) 
and c.1372A>T (p.Lys458X), were introduced 
into the pAHC-SIL1 construct by site-directed 
mutagenesis using the Quick Change Site-
Directed Mutagenesis Kit (Stratagene). The 
primer sequences are available on request. All 
constructs were verified by sequencing the 
entire coding regions of the inserts. 
 
7.3.6 Cell culture and transfections (III) 
 
COS-1 cells (American Type Culture 
Collection) were cultivated in Dulbecco’s 
modified Eagle’s medium (Lonza Walkersville 
Inc.) supplemented with 10% fetal calf serum 
(PromoCell GmbH), penicillin and 
streptomycin, and 1x GlutaMAX (Gibco, 
Invitrogen). The cells (1.5x 105) were plated 
onto 6-well plates on coverslips one day prior 
to transfection, and were transfected with 2 
µg of wild-type or mutated pAHC-SIL1 using 
FuGENE 6 Transfection Reagent (Roche) 
according to the manufacturer’s instructions. 
For immunofluorescence analysis, protein 
production was inhibited by two hours 
incubation with cycloheximide 18 hours after 
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transfection and cells were fixed with 4% 
paraformaldehyde.  
 
Hippocampi of embryonic day 16.5 C57BL 
mice were dissected out in ice-cold 100 mM 
PBS without Ca2+/Mg2+ (PBS, pH 7.4) 
supplemented with 20 mM glucose. Tissue 
was trypsinized by adding 20 ng/ml DNAseI 
and 0.1%/0.4 mM trypsin-EDTA and 
incubating for 5 minutes at 37°C. Trypsin was 
inhibited with fetal calf serum and the tissue 
was further mechanically dissociated. Four 
hippocampi were pooled and resuspended in 
a Neurobasal medium (Gibco, BRL) 
supplemented with 1x B27 (Gibco), glutamine 
and antibiotics. The cells were plated on poly-
D-lysine (Sigma-Aldrich) coated 58 mm dishes 
with coverslips and cultured for 8-14 days. 
The cells were fixed in 4% paraformaldehyde 
in PBS for 20 min. 
 
7.3.7 Immunofluorescence analysis (III) 
 
Transfected COS-1 cells were permeabilized 
with 0.1% Triton X-100 in PBS for 15 min or 
with 0.2% saponin in PBS supplemented with 
0.5% bovine serum albumin for 30 min. 
Mouse or rabbit anti-HA (Covance Research 
Products, clone 16B12, 1:16000; and Santa 
Cruz Biotechnology, Y-11, 1:500, respectively) 
antibodies were used to detect the N-
terminus of the HA-tagged SIL1 protein. To 
differentiate subcellular compartments, rabbit 
anti-GRP78 (Sigma-Aldrich Co, 1:100) and 
mouse anti-PDI (Stressgen, Assay Designs Inc., 
1:50) antibodies were used for ER, rabbit anti-
p58 (kindly provided by R. Pettersson, Ludwig 
Institute for Cancer Research, Sweden) was 
used for ERGIC, sheep anti-TGN46 (Serotec, 
1:200) and rabbit anti-Giantin (BioSite, 
1:1000) were used for Golgi apparatus, and 
mouse anti-Lamp-1 (DSHB, H4A3; developed 
by August, J.T and Hildreth, J.E.K and 
obtained from the Developmental Studies 
Hybridoma Bank developed under the 
auspices of the NICHD and maintained by The 
University of Iowa, Department of Biological 
Sciences, Iowa City, IA, USA; 1:100) was used 
for lysosomes. Secondary antibodies were 
Cy2- or Cy3-conjugated anti-rabbit IgG, Cy2-
conjugated anti-goat IgG, and Cy2- or Cy3-
conjugated anti-mouse IgG (Jackson 
ImmunoResearch, 1:200).  
 
The hippocampal neurons were permeabilized 
with 0.1% Triton X-100 in PBS containing 
0.5% BSA. The primary antibodies were goat 
anti-SIL1 (Abcam Ltd, 1:5), rabbit anti-GRP78 
(Sigma-Aldrich, 1:300), and rabbit anti-PDI 
(Stressgen, 1:50). The secondary antibodies 
were Cy2-conjugated anti-goat-IgG and Cy3-
conjugated anti-rabbit-IgG (Jackson 
ImmunoResearch, 1:250).  
 
7.4 Web resources 
 
Online Mendelian Inheritance in Man (OMIM) 
cataloging human genes and genetic 
disorders is available at http://www.ncbi. 
nlm.nih.gov/entrez/query.fcgi?db=OMIM. 
Three genome browsers, the Ensembl Human 
Genome Browser (http://www.ensembl.org/ 
Homo_sapiens/), NCBI MapViewer (http:// 
www.ncbi.nlm.nih.gov/projects/mapview/map
_search.cgi?taxid=9606), and UCSC Human 
Genome Browser (http://genome.ucsc.edu/ 
cgi-bin/hgGateway), were used in this study. 
 
Microsatellite marker allele numbering was 
determined from the CEPH database 
(http://www.cephb.fr/cephdb/php/eng/). The 
primers used in sequencing were designed 
with either Primer3 (http://frodo.wi.mit.edu/ 




Gene names are according to HUGO Gene 
Nomenclature Committee (http://www.genen 
ames.org/). The recommendations for the 
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description of sequence variants published by 
the Human Genome Variation Society (HGVS) 
(http://www.hgvs.org/mutnomen/) were 
followed in describing the mutations.  
 
The GO database (http://www.geneontology. 
org/) was utilized in prioritizing the positional 
candidate genes on chromosome 5q31. 
Alternatively spliced SIL1 transcripts were 
identified using NCBI AceView (http:// 
www.ncbi.nlm.nih.gov/IEB/Research/Acembly/
index.html). In silico analysis of the c.1030-
9G>A mutation was performed with two 
exon prediction programs. GENSCAN is 
available at http://genes.mit.edu/GENSCAN. 
html and GrailEXP Exon Prediction Program 
(Perceval) at http://compbio.ornl.gov/grailexp/. 
SIL1, HSPA5, and HYOU1 expression patterns 
based on the GNF (Genomics Institute of the 
Novartis Research Foundation) Human Gene 
Expression Atlas 2 database were analyzed 
with the UCSC gene sorter (http://genome. 
ucsc.edu/cgi-bin/hgNear). Expressed sequence 
tags (ESTs) for SIL1 and HSPA5 in different 
ocular regions were found in the NEIBank EST 
database (http://neibank.nei.nih.gov/index. 
shtml). Sequence alignments were made with 
ClustalW (http://www.ebi.ac.uk/clustalw/) and 
Multiple Alignment using Fast Fourier 
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8 RESULTS AND DISCUSSION 
 
8.1 Refinement of the MSS locus (I, II, 
unpublished) 
 
Before the initiation of this study families 
having a subtype of MSS with myoglobinuria 
and neuropathy had been linked to a locus on 
18qter (Merlini et al. 2002), which was 
initially characterized as a locus for the 
congenital cataracts with facial dysmorphism 
and neuropathy (CCFDN) syndrome 
(Angelicheva et al. 1999). Another locus 
spanning a 9.3 cM interval on chromosome 
5q31 had been reported for classical MSS 
(Lagier-Tourenne et al. 2003) shortly after we 
started our study. We pursued the candidate 
locus approach to evaluate whether one of 
the known loci was underlying MSS in 
Finland. For linkage analysis, DNA samples 
were available from 8 affected individuals, 5 
parents, and 8 healthy siblings in two 
families, M1 and M4. In addition, two families 
with samples available from one affected 
individual were identified. Due to the size and 
multiple consanguinity loops in family M1, we 
chose the MLINK program for lod score 
calculations. 
 
8.1.1 Exclusion of the candidate locus on 
chromosome 18qter  
 
We genotyped six polymorphic microsatellite 
markers, D18S844, D18S462, D18S461, 
D18S1122, D18S1095, and D18S70, and 
constructed the haplotypes manually. 
Assuming that a common ancestor and one 
homozygous mutation underlies MSS in 
Finland, we expected to detect homozygosity 
across the linked region. Instead, we found 
that two pairs of affected siblings (M115 and 
M116; M403 and M404) did not share 
haplotypes on 18qter (Figure 5) and another 
pair of siblings, M104 and M110, shared 
haplotypes only partially. Moreover, the two-
point lod scores were < -2 for each marker 
(Table 5) excluding linkage to this region. 
 
8.1.2 Mapping MSS to 5q31 in the  Finnish 
families 
 
We selected 18 polymorphic microsatellite 
markers spanning the chromosome 5q31 
locus (Table 6). We confirmed linkage to this 
locus in family M1, in which meiotic and 
historical recombinations defined a 3.52-Mb 
region between markers D5S479 and 
 
Table 5. Results of two!point linkage analysis on chromosome 18qter. 
          
theta / cM 
marker 
0.000 0.001 0.010 0.050 0.100 0.200 0.300 0.400 
(Marshfield1) 
          
D18S844 !inf !3.599 !1.440 0.088 0.517 0.526 0.295 0.100 116.44 
D18S462 !inf !3.883 !1.622 !0.058 0.362 0.401 0.229 0.082 120.05 
D18S461 !inf !0.595 1.306 2.252 2.272 1.704 0.978 0.364 120.05 
D18S1122 !inf !1.148 0.882 2.071 2.179 1.627 0.879 0.287 122.61 
D18S1095 !inf !5.232 !2.753 !0.741 !0.037 0.305 0.230 0.073 124.11 
D18S70 !inf !6.595 !3.578 !1.070 !0.173 0.290 0.240 0.081 126.00 
1 (Broman et al. 1998) 
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D5S2116 (Figure 6; Study II Supplementary 
Figure 2). Four additional Finnish patients 
from three unrelated families M4, M5, and 
M6 shared the 3.52-Mb haplotype with 
patients from the M1 pedigree, suggesting a 
founder effect (Study II Supplementary Figure 
2). The highest two-point lod score of 7.095 
(at θ=0.000) was obtained with D5S414 for 
families M1 and M4 (Table 6).  
 
8.2 Analysis of the positional 
candidate genes (II, unpublished) 
 
The haplotypes were constructed manually 
and this analysis excluded SAR1B (also called 
SARA2) (Jones et al. 2003) as a positional 
candidate gene. Mutations in SAR1B had 
been identified in patients with chylomicron 
retention disease (CMRD, MIM 246700), 
including one family with CMRD and MSS. 
However, no SAR1B mutations had been 
found in additional 5q31-linked MSS families 
(Lagier-Tourenne et al. 2003). The parents of 
the two patients with CMRD and MSS were 
from a small village in Southern Italy, but 
were not reported to be consanguineous 
(Aguglia et al. 2000). Nevertheless, the 
Figure 5. Haplotypes on chromosome 
18qter. Marker order and location in cM are 
given according to the Marshfield genetic 
map (Broman et al. 1998). The affected 
individuals are indicated with filled symbols 
and for simplicity the individuals in the older 
generations in family M1 are not marked as 
deceased. Only one affected pair of siblings, 
M113 and M114, share haplotypes over the 
region while other pairs of siblings are 
recombinant. 
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patients were homozygous for the markers 
across the refined MSS locus (Jones et al. 
2003) and it therefore remained possible that 
they had two separate recessive diseases. 
 
8.2.1 Genes in the critical region  
 
According to the sequence browsers, the 
3.52-Mb region contained 45 genes or 
pseudogenes (Figure 7 and Table 7). We 
selected genes for sequencing based on their 
tissue expression, GO annotations, and 
known or predicted function. Ten genes, 
highlighted with gray in Table 7, were 
excluded by sequencing the exons and exon-
intron boundaries from genomic DNA of 
patient M113, her parents, patient M203, 
and one Finnish control individual.  
 
 
Table 6. Results of two!point linkage analysis on the MSS locus 5q31. 
           
theta / cM  
marker 
0.000 0.001 0.010 0.050 0.100 0.200 0.300 0.400 
(Marshfield1) (deCODE2) 
           
D5S1995 !inf !1.956 !0.045 0.962 1.090 0.825 0.456 0.156 137.95 135.81 
D5S479 !inf 2.371 3.229 3.297 2.822 1.699 0.773 0.205 141.27 138.82 
D5S1983 1.625 1.619 1.559 1.306 1.019 0.561 0.255 0.078 141.82 138.96 
D5S414 7.095 7.078 6.917 6.200 5.294 3.505 1.888 0.669 141.82 ! 
D5S500 4.352 4.339 4.218 3.686 3.039 1.850 0.888 0.266 140.72 138.96 
D5S476 2.913 2.902 2.809 2.404 1.926 1.104 0.503 0.140 140.72 139.38 
D5S2009 1.134 1.129 1.086 0.902 0.670 0.383 0.174 0.051 142.92 139.38 
D5S2116 1.157 1.177 1.296 1.374 1.218 0.783 0.398 0.130 142.92 139.91 
D5S658 !inf 1.257 2.320 2.838 2.646 1.796 0.896 0.259 142.92 ! 
D5S1979 !inf 1.010 2.069 2.575 2.374 1.552 0.751 0.216 144.06 ! 
1 (Broman et al. 1998), 2 (Kong et al. 2002)      
Figure 6. Haplotypes across the MSS locus in families M1 and M2. In the M1 family four different 
haplotypes were present. The majority of the patients shared the two haplotypes depicted on the 
first two rows. Historical recombinations restricted the candidate region between markers D5S642 
and D5S2116. Patient M104 had a meiotic recombination further narrowing the region to 3.52 
Mb between markers D5S479 and D5S2116. A meiotic recombination present in patient M113 
did not initially narrow the region until a heterozygous SNP rs13385 was detected while 
sequencing the HBEGF gene. The MSS locus was refined to between markers D5S500 and 











































































































chromosom e s  
Patient 
n o .  
                
5  5  2  3  1  8  5  2  1  1  1  3  9  3  5   
1  5  2  3  1  8  5  2  1  1  4  2  5  5  5   
2  2  6  2  1  8  5  2  1  1  4  2  5  5  1  M104  
1  5  2  3  1  8  5  2  1  2  1  5  6  6  1  M113  
1  2  1  2  2  7  9  2  1  0  8  2  1  8  1  M203  
 





The double line on the left indicates the final MSS locus refined by the shared haplotype between th e 
Swedish twins and Finnish patients as well as a meiotic recombination observed in patient M113. 
*  Current gene names are given to hypothetical genes that have been characterized since the release of 
NCBI Build 35.1 (August 2004). 
** These genes have been discontinued since the release of NCBI Build 35.1. 
 
Table 7. Positional candidate genes in the 3.52!Mb MSS locus on chromosome 5q31. 
  
 Symbol  Description 
  SPOCK1 sparc/osteonectin, cwcv and kazal!like domains proteoglycan (testican) 1 
  KLHL3 kelch!like 3 (Drosophila) 
  HNRPA0 heterogeneous nuclear ribonucleoprotein A0 
  NPY6R neuropeptide Y receptor Y6 (pseudogene) 
  MYOT myotilin 
  PKD2L2 polycystic kidney disease 2!like 2 
  C5orf5 chromosome 5 open reading frame 5 
  WNT8A wingless!type MMTV integration site family, member 8A 
  NME5 non!metastatic cells 5, protein expressed in (nucleoside!diphosphate kinase) 
  BRD8 bromodomain containing 8 
  KIF20A kinesin family member 20A 
  CDC23 CDC23 (cell division cycle 23, yeast, homolog) 
  GFRA3 GDNF family receptor alpha 3 
  CDC25C cell division cycle 25C 
  FAM53C family with sequence similarity 53, member C ! hypothetical protein * 
  JMJD1B jumonji domain containing 1B ! hypothetical protein * 
  REEP2 receptor accessory protein 2 ! hypothetical protein * 
  EGR1 early growth response 1 
  ETF1 eukaryotic translation termination factor 1 
  HSPA9B heat shock 70kDa protein 9B (mortalin!2) 
  LOC391836 similar to ribosomal protein L10a 
  CTNNA1 catenin (cadherin!associated protein), alpha 1, 102kDa 
  LOC401210 hypothetical gene supported by AK022326 ! discontinued ** 
  SIL1 SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) 
  MATR3 matrin 3 
  LOC441111 LOC441111 ! discontinued ** 
  PAIP2 poly(A) binding protein interacting protein 2 
  SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 
  PACAP proapoptotic caspase adaptor protein 
  LOC389333 LOC389333 
  LOC389334 LOC389334 ! discontinued ** 
  LOC202051 hypothetical protein LOC202051 
  DNAJC18 DnaJ (Hsp40) homolog, subfamily C, member 18 ! hypothetical protein * 
  LOC340061 hypothetical protein LOC340061 
  LOC401211 similar to nuclear receptor coactivator 4 
  UBE2D2 ubiquitin!conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 
  CXXC5 CXXC finger 5 
  PSD2 PSD2 pleckstrin and Sec7 domain containing 2 ! hypothetical protein * 
  NRG2 neuregulin 2 
  PURA purine!rich element binding protein A 
  C5orf32 chromosome 5 open reading frame 32 
  PFDN1 prefoldin 1 
  HBEGF heparin!binding EGF!like growth factor  
  SLC4A9 solute carrier family 4, sodium bicarbonate cotransporter, member 9 
  ANKHD1 ANKHD1 ankyrin repeat and KH domain containing 1 
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At the same time as we performed the 
candidate gene analysis we found that a pair 
of Swedish monozygotic twins with MSS 
(M203 and M204), whose paternal great 
grandmother was born in Finland, shared the 
Finnish founder haplotype on the paternal 
chromosome between markers D5S500 and 
D5S2116. This defined the Finnish haplotype 
to a region of 1.98 Mb and excluded 17 
genes (Figures 6 and 7, Table 7). In addition, 
M113 had a recombinant SNP (rs13385) in 
the 3’ UTR of the HBEGF gene, which further 
narrowed the critical region and excluded 
three more genes.  
 
8.2.2 Mutations in SIL1 underlie MSS 
 
The 11th gene selected for sequencing was 
SIL1, the ER-resident cochaperone of GRP78. 
Human SIL1 is a 1923 bp transcript encoding 
a 461 amino acid protein. The main transcript 
has ten exons, of which nine are coding, and 
spans a 251.7-kb genomic region (Figure 8). 
One additional 5’ noncoding exon (marked as 
exon 1a) is found at least in placental tissue. 
All Finnish patients were homozygous for a 4-
nucleotide duplication in exon 6 compatible 
with the predicted founder effect. As 
expected, the Swedish patients M203 and 
M204 were compound heterozygotes for the 
Finnish founder mutation and another 
mutation changing the conserved donor 
splice site of intron 6. The analysis of further 
families with MSS from Norway, France, and 
Turkey revealed additional mutations, 
confirming that SIL1 mutations underlie MSS. 
Refining the candidate region using the 
ancestral Finnish haplotype and identifying 
the founder mutation in SIL1 is yet another 
example of exploiting the founder effect in 
disease gene identification (see Section 5.4.5). 
Figure 7. Genes in the 5q31 candidate region. The original 3.52-Mb candidate region is shown. 
The upper bar shows the chromosomal band and each gene is depicted as one solid bar. Blue box 
indicates the final candidate region between D5S500 and rs13385. SIL1 is marked with a red 
arrow. The picture was modified from the Ensembl genome browser view of the region. 
Figure 8. The structure of SIL1 showing the MSS-associated mutations identified in this study. The 
main variant of SIL1 is transcribed from ten exons. The boxes represent the exons. The coding region 
is in red while untranslated regions are in pink. The positions of the mutations are shown with lines. 
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8.3 SIL1 mutations in patients with 
MSS (II, III, unpublished) 
 
We identified a total of eight mutations in the 
SIL1 gene in 29 patients of different ethnic 
origins (Figure 8 and Table 8). The mutations 
were distributed quite evenly throughout 
SIL1. Two mutations, c.331C>T and 
c.1367T>A, were nonsense changes creating 
PTCs: p.Arg111X and p.Leu456X, 
respectively. Three mutations were small 
duplications (c.212dupA, the Finnish founder 
mutation c.506_509dupAAGA, and 
c.936dupG) leading to frameshifts and PTCs 
(p.His71GlnfsX5, p.Asp170GlufsX4, and 
p.Leu313AlafsX39, respectively). Two 
mutations affect splice sites (c.645+2T>C and 
c.1030-9G>A) and their consequences are 
discussed in Section 8.3.2. Only one 
mutation, c.1370T>C, was a missense change 
(p.Leu457Pro). The Swedish patients were 
compound heterozygous for 
c.506_509dupAAGA and c.645+2T>C, while 
all the other patients carried homozygous 
mutations. 
 
All the mutations segregated with the disease 
phenotype in the respective families. One 
carrier for the c.506_509dupAAGA mutation 
was identified among 96 Finnish controls. In 
54 Japanese controls, we detected one carrier 
for the c.936dupG mutation. CEPH controls 
were negative for all the mutations. The 
detection of mutation carriers among healthy 
unrelated controls may imply that the carrier 
 
Table 8. MSS!associated mutations in SIL1. 
     
Location Nucleotide change 
Predicted  
consequence 
Ethnic origin Reference 
     
Exon 3 c.212dupA p.His71GlnfsX5 France II 





(Senderek et al. 2005) 
(Annesi et al. 2007) 
Exon 6 c.506_509dupAAGA p.Asp170GlufsX4 Finland, Sweden, Norway II 




Exon 9 c.936dupG p.Leu313AlafsX39 Japan III 
Intron 9 c.1030!9G>A p.Phe345AlafsX9 Norway III 
Exon 10 c.1367T>A p.Leu456X Turkey III 
Exon 10 c.1370T>C p.Leu457Pro Japan III 
     
Exon 3 c.178C>T p.Glu60X Vietnam (Senderek et al. 2005) 
Exon 4 c.346delG p.Gly116fsX42 Vietnam (Senderek et al. 2005) 
Intron 6 c.645+1G>A skipping of exon 6 Turkey (Senderek et al. 2005) 
Exon 9 c.947_948insT p.Leu316fsX36 Germany, Russia (Senderek et al. 2005) 
Intron 9 c.1029+1G>A skipping of exon 9 Bosnia (Senderek et al. 2005) 
Intron 9 c.1030!18G>A p.Met344fsX13 Germany (Senderek et al. 2005) 
Exon 10 c.1249C>T p.Gln417X Mali (Senderek et al. 2005) 
Exon 10 c.1312C>T p.Gln438X Egypt (Karim et al. 2006) 
Exon 10 c.1366delT p.Leu456fsX2 Russia (Senderek et al. 2005) 
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frequency is relatively high at least in certain 
parts of Finland and Japan.  
 
At the same time as study II was published, 
Senderek et al. independently identified nine 
SIL1 mutations causing MSS (Senderek et al. 
2005). In addition to these mutations, others 
have reported single MSS families with SIL1 
mutations (Karim et al. 2006; Annesi et al. 
2007), summing up the total number of 
mutations to 17 (Table 8). 
 
8.3.1 The geographical distribution of the 
Finnish founder mutation 
 
As discussed above, all the Finnish patients 
were homozygous for c.506_509dupAAGA 
resulting in a frameshift at codon 170 and a 
stop codon after three novel amino acids. The 
Swedish patients had this mutation in their 
paternal allele. The largest Finnish family M1 
originated from Kainuu and the three smaller 
families (M4, M5, and M6) were from 
Ostrobothnia (Figure 9). The paternal great 
grandmother of the Swedish family M2 was 
born in Lapland, Finland. Although it is likely 
that these families are distantly related to 
each other, we were unable to find a 
relationship between the families from parish 
records. In addition, patients in one 
Norwegian family, M12, were homozygous 
for the c.506_509dupAAGA mutation. 
Interestingly, although the Norwegian family 
had no knowledge of Finnish ancestors, it 
originated from the Finnmark county (Skre et 
al. 1976), which is known for receiving 
immigrants from northern Finland. Moreover, 
the patients in family M12 shared the 2–1 
haplotype (markers D5S479 and D5S2009; 
see Figure 6) with Finnish and Swedish 
patients as well as an allele A of a coding SNP 
in SIL1 exon 3 (rs3088052). It thus remains 
possible that the c.506_509dupAAGA 
mutation arose only once and that these 
families share a common ancestor. 
 
8.3.2 Consequences of the splice site 
mutations 
 
The effect of the splice site mutation 
c.645+2T>C was analyzed by RT-PCR from the 
two compound heterozygote patients and 
Figure 9. Origin of the Nordic MSS 
families. The ancestries of the Finnish 
families and the paternal great 
grandmother of the Swedish family 
were from Ostrobothnia, Kainuu, 
and Lapland (filled circles). The 
Norwegian family with the same 
homozygous mutation originated 
from Finnmark county (filled circle), 
but had no known ancestry in 
Finland. The other Norwegian 
mutation was detected in two 
families from northern Norway 
(Troms and Nordland counties) (gray 
circles). The origin of the Swedish 
family with the splice site mutation is 
indicated with a gray triangle. This 
figure is based on an original by 
Teppo Varilo and has been modified 
with his kind permission. 
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their mother who carried this mutation (Study 
II Figure 1). The c.506_509dupAAGA allele 
transcript showed the expected length 
product. Two abnormal sized variants were 
identified from the splice site mutant allele. In 
the shorter variant, expressed at higher levels, 
exon 6 is skipped, predicting an in-frame 
deletion of 64 amino acids (p.Ala152_Gln 
215del). In the longer variant, a cryptic splice 
site in the middle of exon 6 is used, predicting 
an in-frame deletion of 30 amino acids 
(p.Val186_Gln215del). The transcript lacking 
the whole exon 6 seems to be normally 
expressed at low levels as it is seen in controls 
(Study II Figure 1). The longer variant, 
however, is not normally present, which 
implies the functional importance of the 
deleted 30 amino acids. Interestingly, this 
region of SIL1 is rich in serine residues. This 
could point to important phosphorylation sites 
necessary for normal functioning of SIL1. 
Furthermore, the putative model of SIL1–
GRP78 interaction suggests that the major 
interaction site is composed of SIL1 exons 6 
and 9 and that exon 10 provides a minor 
interaction site (Senderek et al. 2005).  
 
The c.1030-9G>A mutation was detected in 
two apparently unrelated families from 
northern Norway (Figure 9). We confirmed by 
RT-PCR that the mutation activates a cryptic 
splice site and leads to the insertion of 7 
nucleotides into the mature mRNA (Study III 
Figure 1). The insertion results in a frameshift 
at codon 345 and truncation of the protein 
product after eight novel amino acids 
(p.Phe345AlafsX9). 
8.3.3 Most SIL1 mutations predict 
premature termination codons 
 
It is noteworthy that 13 of the 17 MSS-
associated SIL1 mutations described so far 
(Table 8) predict a truncated SIL1 protein likely 
to make it non-functional, or for the transcript 
or the protein to be degraded. Eight of these 
mutations introduce PTCs within the amino 
acids encoded by the last exon of SIL1 either 
through a frameshift or a nonsense change. 
Since exon-exon junctions in the transcript 
downstream of the PTC are essential in 
initiating nonsense-mediated mRNA decay 
(Maquat 2004), these eight mutations are 
more likely to produce truncated polypeptides 
than PTC-causing mutations that are located 
more upstream.  
 
The four remaining mutations predict either 
in-frame deleted SIL1 variants due to splice 
site mutations or a missense change. The 
pathogenicity of the in-frame deleted SIL1 
variants could be explained by incorrect 
folding and degradation or absence of 
important functional domains. So far, only 
one missense mutation has been detected in 
SIL1, c.1370T>C (p.Leu457Pro) changing a 
leucine just before the ER retrieval signal at 
position 457 to a cyclic proline (Study III 
Figures 1 and 2). As proline has a built-in bend 
in the backbone, this substitution may create 
a turn in the polypeptide chain (see Section 
8.5.2) hiding the ER retrieval signal located in 
the C-terminus of SIL1. 
 
In addition to the Finnish founder mutation, 
two mutations, c.331C>T and c.947_948insT, 
have each been identified in more than one 
family (Table 8). Recently, the c.331C>T 
mutation was reported in patients with CMRD 
and MSS (see Section 8.2) proving that the 
patients have two recessive diseases due to 
mutations in two genes, SAR1B and SIL1, 
localized on chromosome 5q31. 
 
8.3.4 Genetic heterogeneity in classical 
MSS 
 
SIL1 mutations are not detected in all MSS 
patients presenting the main features of 
cerebellar atrophy and ataxia, early-onset 
cataracts, myopathy, and mental retardation 
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(Study III, Senderek et al. 2005). Genetic 
heterogeneity, e.g. disease associated 
mutations at more than one locus, is a rather 
common phenomenon in inherited disorders, 
and is most likely present in MSS too. As 
cDNA analysis has not been performed for all 
MSS patients without SIL1 mutations, we 
can’t rule out the possibility that some of the 
mutation negative patients may have 
deleterious changes affecting the intronic 
regions that would not be detected by 
analyzing the coding regions of SIL1 from 
genomic DNA.  
 
8.4 Expression analysis of SIL1 (II) 
 
Previous Northern analysis of SIL1 expression 
in adult human tissues had shown a 1.8-kb 
transcript with highest levels in secretory 
organs, a relatively high level in skeletal 
muscle, and low expression in the brain 
(Chung et al. 2002). Based on database ESTs 
and RT-PCR experiments (see below), 
alternative splicing is relatively frequent in 
SIL1. The 3’ end of SIL1 contains two 
polyadenylation sites. Both of these sites may 
be used, as supporting EST sequences are 




8.4.1 Expression of SIL1 in patient muscle 
tissue 
 
We studied the expression of SIL1 in skeletal 
muscle biopsies of MSS patients and controls 
using an antibody detecting a C-terminal 
epitope “ELLGSVNSLLKELR”. In control muscle 
cross sections, SIL1 immunoreactivity 
appeared as discrete subsarcolemmal 
crescents often in close vicinity to nuclei 
(Study II Figure 1c), which is the location of 
rough ER in myofibers. In Finnish patients, 
homozygous for p.Asp170GlufsX4, no definite 
subsarcolemmal immunostaining was 
observed, compatible with the predicted 
truncation of the polypeptide and loss of the 
epitope. Whether these patients express a 
truncated protein remains unknown. In the 
compound heterozygous Swedish patients 
(M203 and M204) with two abnormally sized 
in-frame deleted variants, p.Ala152_Gln 
215del and p.Val186_Gln215del, the 
immunostaining was similar to the controls, 
indicating that the in-frame deleted variant(s) 
from the splice site mutation allele are 
translated to proteins. Compatible with the 
loss-of-function effect of this mutation, it is 
thus likely that the exon 6 encoded amino 
acids are critical for normal SIL1 function. 
Although the exon 6 in-frame deleted variant 
is present at low levels in control individuals, 
the total loss of normal variant seems to be 
pathogenic, which is also supported by the 
finding of another splice site mutation leading 
to skipping of exon 6 (Senderek et al. 2005). 
Interestingly, there was no evidence of SIL1 
positive aggregate formation in the muscle 
expressing the exon 6 in-frame deleted 
variants, contrary to the findings in the wz 
mouse mutant and overexpressed mutant SIL1 
proteins in COS-1 cells (see Section 8.5). It 
thus remains possible that the in-frame 
deleted variant is stable and nonaggregating, 
but nonfunctional due to conformational 
changes. 
 
8.4.2 Expression of SIL1 in human tissues  
 
We investigated SIL1 expression in human 
fetal and adult tissues with emphasis on the 
brain. Northern analysis showed SIL1 
expression in all adult brain regions, but not 
in fetal brain (Study II Supplementary Figure 
4a). RT-PCR analysis, however, revealed SIL1 
expression also in fetal brain indicating lower 
expression in developing brain (Study II 
Supplementary Figure 4b). Since SIL1 acts as 
an adenine nucleotide exchange factor for 
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GRP78 (see Section 5.6.3), we wanted to see 
whether the expression pattern of these two 
proteins and their respective genes, SIL1 and 
HSPA5, overlap. According to the Human 
Gene Expression Atlas 2 database, SIL1 and 
HSPA5 to have highly similar tissue 
expression, with highest expression in liver, 
pancreatic islets, lung, prostate, thyroid, and 
placenta, and relatively low expression in 
neuronal tissues. Searching for the NEIBank 
Expressed Sequence Tags showed SIL1 and 
HSPA5 expression in fetal whole eye and in 
adult human lens, retinal pigment 
epithelium, and choroid.  
 
8.4.3 Expression of SIL1 in mouse tissues 
 
Given the cerebellar atrophy, congenital 
cataract, and progressive myopathy of MSS 
patients, we investigated the temporal and 
spatial expression of SIL1 and GRP78 
(denoted as Hspa5 in Study II Supplementary 
Figure 5) in mouse tissues. In fetal tissues 
(embryonal day 12.5 to 18.5), SIL1 and 
GRP78 exhibit similar expression patterns in 
cells of developing retina, lens, and brain 
(Study II Supplementary Figure 5). From 
postnatal day 5 onwards both SIL1 and 
GRP78 are expressed in cortical neurons 
especially on layers I-IV throughout the 
brain, in cerebellar Purkinje and granule 
cells, and in hippocampal neurons (Study II 
Supplementary Figure 5). In hippocampus, 
SIL1 expression was somewhat stronger in 
the pyramidal neurons of the CA3 region, 
while GRP78 was more uniformly expressed 
in all regions. In addition to the CNS, similar 
expression of SIL1 and GRP78 was seen in 
several other tissues including muscle, 
developing bone, cartilage, and gonads 
(data not shown). 
 
8.4.4 SIL1 tissue expression patterns and 
manifestations of MSS 
 
The tissue and subcellular expression patterns 
of SIL1/SIL1 and HSPA5/GRP78 are highly 
similar, suggesting related functions in vivo for 
the two proteins, in agreement with their 
demonstrated interaction in cellular models 
(Boisrame et al. 1998; Tyson et al. 2000; 
Chung et al. 2002). Interestingly, no clinical 
symptoms have been reported from tissues 
showing the highest SIL1 expression levels 
such as liver and pancreas, suggesting that 
certain cells and tissues, including cerebellar 
neurons, skeletal muscle and lens cells, lack 
compensatory mechanisms or are more 
sensitive to disturbed cellular homeostasis. It is 
possible that other nucleotide exchange 
factors can compensate for the loss of SIL1 in 
the non-vulnerable tissues. In line with this 
prediction, Sil1p is non-essential for viability in 
yeast (Tyson et al. 2000), where Lhs1p acts as 
a nucleotide exchange factor for Kar2p in a 
mutually exclusive manner to Sil1p (Steel et al. 
2004), accounting for the lethality of 
Δlhs1Δsil1 double mutants (Tyson et al. 2000). 
The human LHS1 homologue, HYOU1 has a 
tissue expression pattern partially different 
from that of SIL1, e.g. HYOU1 is almost 
absent from skeletal muscle, and the HYOU1 
protein might thus compensate for SIL1 in 
some tissues.  
 
It is noteworthy that the distribution of 
affected tissues in MSS shows similarities with 
the tissue distribution in some other 
disorders. The group of O-mannosylation 
disorders, Walker-Warburg syndrome (WWS), 
Fukuyama congenital muscular dystrophy 
(FCMD), and muscle-eye-brain disease (MEB), 
are similar to MSS with respect to the main 
affected tissues including brain, muscle, and 
eye (van Reeuwijk et al. 2005a). Interestingly, 
yeast Sil1 has been suggested to have a 
genetic interaction with Pmt2 (Schuldiner et 
al. 2005), which corresponds to the human 
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POMT2 gene. POMT2 together with POMT1 
is responsible for the protein O-
mannosyltransferase enzyme activity, which is 
defective in a subset of patient with WWS 
(van Reeuwijk et al. 2005b). It remains to be 
seen whether SIL1 has a more specific role 
related to processing of O-mannosylated 
proteins.  
 
8.5 Subcellular localization of SIL1 and 
its mutants (III)  
 
Previously, exogenously expressed SIL1 had 
been demonstrated to localize to the ER in 
transfected COS-1 cells (Chung et al. 2002). 
This finding is in accordance with the known 
SIL1 function as a nucleotide exchange 
factor for GRP78 and the presence of N-
terminal ER targeting and C-terminal ER 
retrieval sequences in SIL1. Just prior to the 
publication of SIL1 mutations underlying 
MSS, a truncation of Sil1 was shown to 
cause ataxic phenotype in wz mutant mouse 
(Zhao et al. 2005) (see also Section 5.6.3). 
Interestingly, the affected wz mutant 
Purkinje cells showed ubiquitin-positive 
protein accumulations within the ER and the 
nucleus. 
 
8.5.1 SIL1 localizes to the endoplasmic 
reticulum in cultured mouse neurons 
 
We studied whether endogenous SIL1 
localizes to the ER in cultured mouse primary 
hippocampal neurons. Using 
immunofluorescence analysis, we found SIL1 
to predominantly localize to the ER, which 
was indicated by colocalization with the ER 
marker PDI (Study III Figure 4). SIL1 also 
colocalizes with GRP78 in neurons, however, 
no colocalization was detected with a Golgi 
marker (data not shown). This finding was 
well in line with previous localization studies 
in transiently transfected COS-cells (Chung 
et al. 2002; Zhao et al. 2005). 
 
8.5.2 Subcellular localization of the wild-
type and mutant SIL1 proteins 
 
We chose two mutations for the subcellular 
localization studies. The missense 
substitution p.Leu457Pro detected in 
patients changes a leucine to a cyclic proline 
and may thus influence the tertiary structure 
of SIL1 by creating a turn in polypeptide and 
hiding the assumed ER retrieval tetrapeptide 
present at the very end of the protein (Figure 
3). Since several mutations creating a 
premature stop codon in exon 10 have been 
described (Table 8), we decided to create an 
artificial mutation deleting only the predicted 
ER retrieval signal at the very end of the 
protein product (p.Lys458X).  
 
We transiently transfected COS-1 cells with 
wild-type and mutant SIL1 with HA-tags in 
order to find out whether mutant SIL1 had 
normal subcellular localization. The 
exogenous wild-type SIL1 protein colocalized 
with both the ER and the Golgi apparatus 
markers (Study III Figure 3) in our 
experiments. Given the ER localization of the 
endogenously expressed SIL1, overproduction 
of the protein may lead to its escape from the 
ER into the Golgi apparatus, a phenomenon 
that has been seen with some other proteins 
possessing weaker ER retrieval signals (Lewis 
et al. 1992).  
 
We hypothesized that the missense mutation 
(p.Leu457Pro) and the mutation deleting the 
ER retrieval motif (p.Lys458X) would lead to 
defective retrieval of the mutant protein from 
later stages of the secretory pathway. Both 
mutant proteins clearly showed altered 
localization compared to wild-type SIL1: in 
cells with higher expression levels, mutant 
proteins formed aggregates that showed ER 
localization while in cells with lower 
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expression levels mutant SIL1 was present in 
the ER without aggregate formation (Study III 
Figure 3). The aggregates showed strongest 
overlap with GRP78 and PDI markers and they 
did not overlap with any of the ER-Golgi 
intermediate compartment, Golgi apparatus, 
or lysosome markers (Study III Figure 3 and 
data not shown). In some cells, GRP78 
staining was more pronounced in the 
aggregates, suggesting that it is present in 
these structures as would be expected 
knowing its function in targeting misfolded 
proteins to degradation (see Section 5.6.2).  
 
To summarize, the pathogenicity of the 
Leu457Pro and Lys458X mutant proteins is 
explained both by abnormal subcellular 
localization and by structural changes making 
them prone to aggregate formation. The 
same mechanisms could occur with other 
mutations leading to truncation of the SIL1 
protein within exon 10. It is interesting to 
note that the wz mutant mouse also shows 
protein accumulations prior to cerebellar 
Purkinje cell degeneration. The accumulations 
are ubiquitinated and show positive 
immunostaining for several ER chaperones 
including GRP78 and GRP94. However, the 
biochemical composition of the aggregates 
present in wz Purkinje cells remains unknown 
(Zhao et al. 2005). 
 
8.6 Exclusion of functional candidate 
genes in MSS (III) 
 
As previously discussed, MSS is genetically 
heterogeneous and SIL1 mutations are not 
found in all patients with typical clinical 
findings. Given the functional interaction 
between SIL1 and GRP78 and the fact that 
HYOU1 can substitute for SIL1 function, we 
chose to study the respective genes, HSPA5 
and HYOU1, for mutations in patients 
without SIL1 mutations. Hspa5 and Hyou1 
mouse knockout models show embryonic 
lethality (Ni et al. 2007), but we reasoned that 
other than loss-of-function mutations could 
play a role in MSS. Subsequently, the AARS 
gene was also selected as a possible 
functional candidate because of the similarity 
between the cerebellar phenotypes of the Sil1 
and Aars mouse models (Zhao et al. 2005; 
Lee et al. 2006). Analyzing a panel of 18 
patients with MSS, we found no disease-
causing alterations within the coding regions 
of HSPA5, HYOU1, and AARS. A possibility 
remains that in a subset of patients a 
mutation is located in the intronic regions of 
these genes and was therefore not identified 
by sequencing genomic DNA. Nevertheless, 
according to our data, HSPA5, HYOU1, and 
AARS are unlikely to be major genes 
underlying MSS. 
 
8.7 Clinical findings in patients with 
SIL1 mutations (I – III, unpublished) 
 
The approximately 200 patients with MSS 
reported so far present marked variability in 
their clinical features. Identification of SIL1 as 
the gene underlying MSS is the first step 
towards the classification of MSS and related 
disorders likely to be clinically and genetically 
heterogeneous. Moreover, the molecular 
genetic characterization of SIL1 mutations 
underlying classical MSS allows definition of 
more precise diagnostic criteria. Even with the 
current data, the patients may be classified 
into two groups. In classical MSS all the 
hallmark features are present as well as a 
variety of additional features. In the MSS-like 
group some, but not all, of the cardinal 
features are present together with several 
atypical symptoms. In some patients clear 
distinction cannot be made; one hallmark 
feature may not exist or some atypical 
symptoms may be present. The boundaries 
between the two groups are likely to change 
in the future as the number of SIL1 mutation 
positive cases grows and additional genes 
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underlying MSS are described. 
 
In the present study, detailed clinical 
information was available from 29 patients 
with MSS and proven SIL1 mutations. In 
addition, clinical information was available on 
patient M705, the sister of M704, for whom 
no DNA analysis was performed (Table 9). All 
these 30 patients had classical MSS. Although 
more thorough clinical characterization of this 
group is needed, some notes about the 
classical MSS features can be made. Cerebellar 
atrophy was present in all the patients for 
whom brain imaging was performed. With 
 
Table 9. Comparison between the clinical features of SIL1 mutation positive 
patients with MSS and patients described earlier in the literature. 
   
 Patients with  
SIL1 mutations 
30 cases 
(Slavotinek et al. 
2005) 
75 cases 
Cerebellar signs   
   Truncal / limb ataxia 100% (29/29) 72% 
   Dysarthria 100% (6/6) 45% 
   Nystagmus 69% (20/29) 36% 
   Intention tremor  16% 
   Cerebellar atrophy 100% (26/26)  
   
Ophthalmological features   
   Cataracts 100% (30/30) 91% 
   Strabismus 89% (24/27) 44% 
   
Other neurological signs   
   Truncal / limb hypotonia 100% (29/29) 53% 
   Muscle atrophy  51% 
   Muscle weakness 100% (9/9) 36% 
   Myopathic changes 92% (23/25)  
   
Mental retardation (mild to profound) 100% (30/30)  
   
Ortopedic manifestations 62% (16/26)  
   Pes planus / planovalgus  28% 
   Genu valgum  20% 
   Scoliosis 69% (6/9) 19% 
   Kyphoscoliosis  16% 
   Joint contractures  17% 
   Pectus deformities  9% 
   
Endocrinological signs   
   Hypergonadotropic hypogonadism 90% (19/21)  
   
Growth   
   Short stature 60% (18/30)  
   Microcephaly 7% (2/28)  
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brain MRI, cerebellar atrophy was more 
pronounced in the vermis than in the 
hemispheres (Study II Supplementary Figure 
1). Patient M603 showed a T2-hyperintense 
cerebellar cortex (data not shown), which was 
recently reported as one neuroradiological 
feature of MSS (Harting et al. 2004). Ataxia 
and hypotonia were noted in all patients.  
 
In study II, cataracts were diagnosed in all 21 
patients after the age of 2.5 years and in 
some patients a rapid progression of cataracts 
was evident. Prior to development of bilateral 
cataracts, patients M203, M204 and M503 
(families M2 and M5) underwent eye 
examination with normal results. Cataracts 
appeared at six years of age in M1603 (family 
M16) and at 4.5 and 6.5 years of age in 
patients M1105 and M1106 (family M11). Eye 
examination 3-6 months before the onset of 
cataracts revealed microcrystalline opacities in 
only one of the patients.  
 
In study I, we suggested that the progressive 
myopathy characterized by marked muscle 
atrophy together with fat and connective 
tissue replacement is a hallmark feature of 
MSS. The duration of the disease does not 
alone explain the variation in the severity of 
the muscle involvement. Moreover, studying 
nine Finnish patients homozygous for the 
same SIL1 mutation we were able to show 
that the severity of the muscle symptoms can 
vary from moderate to severe. Mental 
retardation is another symptom with 
remarkable variation in severity and most 
patients are mildly or moderately affected. 
 
The additional features often present in 
classical MSS include hypergonadotropic 
hypogonadism, orthopedic manifestations, 
short stature, and strabismus. Many of the 
additional symptoms seemed to be more 
frequent in our patient series than in previous 
reports. For example, skeletal abnormalities 
were present in 62% of the patients with SIL1 
mutations. Although no definite analysis was 
possible due to the small number of cases in 
study I, a tendency of more severe scoliosis 
and longer disease duration together with 
more pronounced myopathy was noted. 
According to the available data, no clear 
correlation exists between the site of the SIL1 
mutation and the clinical phenotype of 
patients with MSS. Only one feature shows 
putative correlation with the location of the 
mutation or mutation type. The two Japanese 
patients (M2103 and M2104) with the 
missense mutation p.Leu457Pro in exon 10 
have normal levels of FSH, LH, and 
testosterone, and show no sign of 
hypogonadism. Interestingly, there is a third 
patient without hypergonadotropic 
hypogonadism and he is a compound 
heterozygote for a mutation in exon 10 
(p.Leu456fsX2) and another frameshift 
(p.Leu316fsX36) (Senderek et al. 2005). On 
the contrary, in a family described by Karim et 
al. where the mutation is located more 
upstream (p.Gln438X), two of the cases show 
either primary amenorrhea or hypogonadism 
(Karim et al. 2006). In the case of the 
p.Leu457Pro mutation, the lack of gonad 
phenotype is not easily explained given the 
fact that the missense mutant protein seemed 
to be prone to aggregation (see Section 
8.5.2). One possible explanation is that the 
terminal mutations prone to aggregation 
maintain some level of function, which would 
be enough to prevent gonadal dysfunction. 
Another possibility is that other genetic or 
environmental factors, like febrile illnesses, 
play a role in the pathogenesis. It remains to 
be seen whether the other patients with C-
terminal mutations or in-frame deletions have 
hypergonadotropic hypogonadism. 
 
In study III we did not identify SIL1 mutations 
in all patients fulfilling the clinical diagnosis 
showing that classical MSS is heterogeneous. 
Moreover, no SIL1 mutations were identified 
in patients belonging to the MSS-like group 
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and lacking more than one hallmark feature 
as well as having several atypical features. 
Our findings are well in line with previous 
reports noting heterogeneity in classical MSS 
(Senderek et al. 2005) and lack of SIL1 
mutations or linkage to 5q31 in the atypical, 
MSS-like group (Lagier-Tourenne et al. 2003; 
Schulz et al. 2007). 
 
In conclusion, this study demonstrates that 
SIL1 mutations are associated with the 
classical MSS phenotype including cerebellar 
atrophy and ataxia, cataracts, myopathy, and 
psychomotor delay. The clinical symptoms of 
patients with SIL1 mutations are rather similar 
(Table 9) and they form a clinically definable 
subgroup among the heterogeneous group of 
MSS patients described earlier in the literature. 
The most evident differences are that 
hypotonia, skeletal abnormalities, and 
hypergonadotropic hypogonadism are more 
frequent features of MSS than previously 
reported. At odds with some previous reports, 
the cataracts may present in early childhood 
rather than being congenital. This is important 
to notice when considering the differential 
diagnosis for other disorders resembling MSS.  
 
8.8 MSS – a protein misfolding and 
accumulation disease? 
 
Several pieces of information suggest that 
MSS pathogenesis is linked to abnormal 
protein quality control in the ER. Chaperone 
GRP78 has multiple roles in processing 
proteins targeted to the secretory pathway 
(Hendershot 2004). As cochaperone, SIL1 
regulates the ATPase cycle of GRP78. Most of 
the SIL1 mutations described so far are 
predicted to lead to nonfunctional or absent 
SIL1 and are thus likely to result in decreased 
rates of GRP78 hydrolysis and abnormal 
protein translocation and folding (Figure 10). 
The accumulation of unfolded proteins in the 
ER causes ER stress, and if stressful conditions 
are not alleviated this may lead to cell death 
(Ma et al. 2004). In addition to the prior 
pathogenetic mechanisms, our results in the 
mutant SIL1 expression studies imply that 
missense changes and some truncations in the 
SIL1 polypeptide may lead to conformational 
alterations making the polypeptide prone to 
aggregation and thus nonfunctional.  
 
The hypothesis of defective protein folding in 
MSS is supported by data from the wz mouse. 
In the wz Purkinje cells loss-of-function of SIL1 
causes induction of the unfolded protein 
response and abnormal accumulation of 
proteins, which is followed by 
neurodegeneration (Zhao et al. 2005). The 
accumulations in wz Purkinje cells contain 
several ER chaperones, including GRP78 and 
GRP94, but it remains to be studied whether 
truncated SIL1 could also be present. Another 
interesting aspect is the survival of a subset of 
cerebellar Purkinje cells in MSS and in the wz 
mouse mutant. The vestibulocerebellum, in 
which the Purkinje cells do not degenerate, is 
the phylogenetically oldest part of the 
cerebellum that receives input from the 
vestibular nuclei in the brainstem. The Purkinje 
cells in the vestibulocerebellum must therefore 
have alternative chaperones to SIL1. 
Establishing the differences between the 
Purkinje cell populations may help to clarify 
the pathogenesis of MSS and give rise to 
future treatment options. 
 
MSS may thus be added to the growing 
number of protein misfolding and 
accumulation disorders due to defective 
molecular chaperone function (Barral et al. 
2004; Muchowski et al. 2005). Mutations in 
other chaperone encoding genes have been 
associated with hereditary cataracts (Litt et al. 
1998) and neuromuscular disorders (Vicart et 
al. 1998; Hansen et al. 2002; Selcen et al. 
2003; Evgrafov et al. 2004; Irobi et al. 2004). 
The autosomal recessively inherited MSS is the 
first human disorder linked to the most highly 
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conserved HSP70 chaperones and, unlike 
many chaperone-associated disorders, it 
displays a wide spectrum of symptoms 
including the involvement of the central 
nervous system, skeletal muscle, lens, bone, 





Figure 10. Role of SIL1 in the pathogenesis of MSS. In normal cells the ATPase cycle of 
GRP78 regulates its binding and release from nascent protein chains as is shown in Figure 2 
(see Chapter 5.6.2). Nucleotide exchange factor SIL1 catalyzes the release of ADP allowing 
the rebinding of ATP on GRP78 (3). In cells lacking SIL1 the ATPase cycle of GRP78 is 
disrupted (MSS). GRP78 can still bind and lock onto the unfolded substrates, but without 
SIL1 GRP78 fails to be released and recycled, which may lead to accumulation of unfolded 
substrates. 
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9 CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
In this thesis, the identification and 
characterization of SIL1, the first and most 
common gene underlying MSS, is described. 
This gives a basis for the molecular genetic 
diagnostics of MSS. However, future work is 
needed to give a more comprehensive view of 
the clinical findings in patients with SIL1 
mutations and establishing diagnostic criteria 
for classical MSS and MSS-like syndromes. 
 
Most of the SIL1 mutations underlying MSS 
result in PTCs and are predicted to lead to 
absence of the SIL1 protein due to mRNA 
decay. A few mutations are assumed to lead 
to absence of functional SIL1 due to loss of 
important functional domains, e.g. the in-
frame deletions of exons 6 and 9, or due to 
aggregate formation, which was seen with 
the p.Leu457Pro missense mutation. In 
addition, aggregate formation leading to 
nonfunctional SIL1 is predicted to be the 
pathogenetic mechanism of the mutations 
leading to PTC within the last exon of SIL1.  
 
Not all patients with a clinical MSS diagnosis 
have detectable mutations in the SIL1 gene 
implying genetic heterogeneity. Functional 
candidate gene analysis failed to identify 
additional genes underlying MSS when 
focusing on the close chaperone partners of 
SIL1, namely GRP78 and HYOU1, and the 
similarity of the cerebellar phenotype of the 
Aars mouse model. Further analysis of 
potential functional candidate genes together 
with identification and genome wide analysis 
of extended or consanguineous families 
without SIL1 mutations is needed to 
characterize other genes underlying MSS. The 
characterization of other MSS genes may 
couple them with SIL1 function and elucidate 
the defective pathway. 
 
Although SIL1 is a protein with established 
nucleotide exchange factor function, little is 
known about its role in multiple tasks carried 
out by GRP78. As alternative nucleotide 
exchange factors exist in the ER, SIL1 could 
participate in a subset of GRP78 tasks or be 
substrate specific. The experimental work 
done on model organisms such as yeast may 
give some clues to the basic biochemical 
pathways that are defective in MSS and 
possibly link MSS to certain protein 
modification processes, such as O-
mannosylation. More importantly, establishing 
the differences between the degenerating and 
surviving wz mouse Purkinje cell populations 
may help to clarify the pathogenesis of MSS. 
Although the wz mice do not show symptoms 
in other MSS-associated organs, the animal 
model is a good basis for studying future 
treatment options in more detail.  
 
The relevance of accumulating proteins in the 
pathogenesis of MSS needs clarification. On 
one hand the mutant SIL1 proteins are prone 
to aggregation and on the other hand the 
absence of SIL1 leads to accumulation of as 
yet unknown proteins in the wz mouse. 
Furthermore, only some human cells and 
tissues seem to be vulnerable to the loss-of-
function of SIL1. Unraveling the interaction 
partners and potential substrates of SIL1 as 
well as defective pathways in MSS may also 
give some basic information about neuronal 
function and survival, and aid in the 
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